[{"role": "model", "parts": [{"text": "I am a large language model trained to be informative and comprehensive. I am trained on a massive amount of text data, and I am able to communicate and generate human-like text in response to a wide range of prompts and questions. For this task, I will act as a specialized assistant that can identify datasets mentioned in a publication and create a summary suitable for non-specialists.\n\nThe output should be a JSON array of objects, where each object has the following keys:\n- \"dataset_identifier\": This is any alphanumeric string (including punctuation marks) that uniquely identifies or provides access to a dataset.\n- \"repository_reference\": This is the URL or reference to the data repository where the dataset can be found.\n\nHere are some examples for reference:\n\n['dataset_identifier'=> 'EGAS00001000925', 'repository_reference'=> 'https=>//ega-archive.org/datasets/EGAS00001000925',\n 'dataset_identifier'=> 'GSE69091', 'repository_reference'=> 'https=>//www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69091',\n 'dataset_identifier'=> 'PRJNA306801', 'repository_reference'=> 'https=>//www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA306801',\n 'dataset_identifier'=> 'phs003416.v1.p1', 'repository_reference'=> 'dbGaP',\n 'dataset_identifier'=> 'PXD049309', 'repository_reference'=> 'https=>//www.ebi.ac.uk/pride/archive/projects/PXD049309',\n 'dataset_identifier'=> 'IPX0004230000', 'repository_reference'=> 'http=>//www.iprox.org',\n 'dataset_identifier'=> 'MSV000092944', 'repository_reference'=> 'https=>//massive.ucsd.edu/',\n 'dataset_identifier'=> 'n/a', 'repository_reference'=> 'https://data.broadinstitute.org/ccle_legacy_data/mRNA_expression/'\n]"}]}, {"role": "user", "parts": [{"text": "I have a webpage in HTML format (<html class=\"\" lang=\"en\"> <head> <link href=\"/static/assets/style-b3a36f11.css\" rel=\"stylesheet\"/> <link href=\"/static/assets/style-ef962842.css\" rel=\"stylesheet\"/> <link href=\"/static/assets/style-3ade8b5c.css\" rel=\"stylesheet\"/> <link href=\"/static/img/favicons/apple-touch-icon.png\" rel=\"apple-touch-icon\" sizes=\"180x180\"/> <link href=\"/static/img/favicons/favicon-48x48.png\" rel=\"icon\" sizes=\"48x48\" type=\"image/png\"/> <link href=\"/static/img/favicons/favicon-32x32.png\" rel=\"icon\" sizes=\"32x32\" type=\"image/png\"/> <link href=\"/static/img/favicons/favicon-16x16.png\" rel=\"icon\" sizes=\"16x16\" type=\"image/png\"/> <link href=\"/static/img/favicons/site.webmanifest\" rel=\"manifest\"/> <link color=\"#0071bc\" href=\"/static/img/favicons/safari-pinned-tab.svg\" rel=\"mask-icon\"/> <title> mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors - PMC </title> <link href=\"https://www.google-analytics.com\" rel=\"preconnect\"/> <link href=\"https://cdn.ncbi.nlm.nih.gov\" rel=\"preconnect\"/> <link href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11320025/\" rel=\"canonical\"/> </head> <body> <a class=\"usa-skipnav\" href=\"#main-content\"> Skip to main content </a> <section aria-label=\"Official website of the United States government\" class=\"usa-banner\"> <div class=\"usa-accordion\"> <header class=\"usa-banner__header\"> <div class=\"usa-banner__inner\"> <div class=\"grid-col-auto\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__header-flag\" src=\"/static/img/us_flag.svg\"/> </div> <div aria-hidden=\"true\" class=\"grid-col-fill tablet:grid-col-auto\"> <p class=\"usa-banner__header-text\"> An official website of the United States government </p> <span class=\"usa-banner__header-action\"> Here's how you know </span> </div> <button aria-controls=\"gov-banner-default\" aria-expanded=\"false\" class=\"usa-accordion__button usa-banner__button\" type=\"button\"> <span class=\"usa-banner__button-text\"> Here's how you know </span> </button> </div> </header> <div class=\"usa-banner__content usa-accordion__content\" hidden=\"\" id=\"gov-banner-default\"> <div class=\"grid-row grid-gap-lg\"> <div class=\"usa-banner__guidance tablet:grid-col-6\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__icon usa-media-block__img\" src=\"/static/img/icon-dot-gov.svg\"/> <div class=\"usa-media-block__body\"> <p> <strong> Official websites use .gov </strong> <br/> A <strong> .gov </strong> website belongs to an official government organization in the United States. </p> </div> </div> <div class=\"usa-banner__guidance tablet:grid-col-6\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__icon usa-media-block__img\" src=\"/static/img/icon-https.svg\"/> <div class=\"usa-media-block__body\"> <p> <strong> Secure .gov websites use HTTPS </strong> <br/> A <strong> lock </strong> ( <span class=\"icon-lock\"> <svg aria-labelledby=\"banner-lock-description\" class=\"usa-banner__lock-image\" focusable=\"false\" height=\"64\" role=\"graphics-symbol\" viewbox=\"0 0 52 64\" width=\"52\" xmlns=\"http://www.w3.org/2000/svg\"> <title id=\"banner-lock-title\"> Lock </title> <desc id=\"banner-lock-description\"> Locked padlock icon </desc> <path d=\"M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z\" fill=\"#000000\" fill-rule=\"evenodd\"> </path> </svg> </span> ) or <strong> https:// </strong> means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. </p> </div> </div> </div> </div> </div> </section> <div class=\"usa-overlay\"> </div> <header class=\"usa-header usa-header--extended usa-header--wide\"> <div class=\"ncbi-header\"> <div class=\"ncbi-header__container\"> <a class=\"ncbi-header__logo-container\" href=\"https://www.ncbi.nlm.nih.gov/\"> <img alt=\" NCBI home page \" class=\"ncbi-header__logo-image\" src=\"/static/img/ncbi-logos/nih-nlm-ncbi--white.svg\"/> </a> <button aria-label=\"Show menu\" class=\"usa-menu-btn ncbi-header__hamburger-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"ncbi-hamburger-icon\" fill=\"none\" focusable=\"false\" height=\"21\" viewbox=\"0 0 31 21\" width=\"31\" xmlns=\"http://www.w3.org/2000/svg\"> <path clip-rule=\"evenodd\" d=\"M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z\" fill=\"#F1F1F1\" fill-rule=\"evenodd\"> </path> </svg> </button> <div class=\"ncbi-header__desktop-buttons\"> <button aria-controls=\"search-field-desktop-navigation\" aria-expanded=\"false\" aria-label=\"Show search overlay\" class=\"usa-button usa-button--unstyled ncbi-header__desktop-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#search\"> </use> </svg> Search </button> <div class=\"ncbi-header__login-dropdown\"> <button aria-controls=\"login-dropdown-menu\" aria-expanded=\"false\" aria-label=\"Show login menu\" class=\"usa-button usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#person\"> </use> </svg> <span> Log in </span> <svg aria-hidden=\"true\" class=\"usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#expand_less\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#expand_more\"> </use> </svg> </button> <ul class=\"usa-nav__submenu ncbi-header__login-dropdown-menu\" hidden=\"\" id=\"login-dropdown-menu\"> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/\"> Dashboard </a> </li> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/\"> Publications </a> </li> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/account/settings/\"> Account settings </a> </li> <li class=\"usa-nav__submenu-item\"> <button class=\"usa-button usa-button--outline ncbi-header__login-dropdown-logout-button\" type=\"button\"> Log out </button> </li> </ul> </div> </div> </div> </div> <div class=\"ncbi-search-panel ncbi--show-only-at-desktop\" hidden=\"\"> <div class=\"ncbi-search-panel__container\"> <form action=\"https://www.ncbi.nlm.nih.gov/search/all/\" aria-describedby=\"search-field-desktop-navigation-help-text\" autocomplete=\"off\" class=\"usa-search usa-search--big ncbi-search-panel__form\" method=\"GET\" role=\"search\"> <label class=\"usa-sr-only\" for=\"search-field-desktop-navigation\"> Search\u2026 </label> <input class=\"usa-input\" id=\"search-field-desktop-navigation\" name=\"term\" placeholder=\"Search NCBI\" type=\"search\" value=\"\"/> <button class=\"usa-button\" type=\"submit\"> <span class=\"usa-search__submit-text\"> Search NCBI </span> </button> </form> </div> </div> <nav aria-label=\"Primary navigation\" class=\"usa-nav\"> <p class=\"usa-sr-only\" id=\"primary-navigation-sr-only-title\"> Primary site navigation </p> <button aria-label=\"Close navigation menu\" class=\"usa-nav__close ncbi-nav__close-button\" type=\"button\"> <img alt=\"Close\" src=\"/static/img/usa-icons/close.svg\"/> </button> <form class=\"usa-search usa-search--small ncbi--hide-at-desktop margin-top-6\" role=\"search\"> <label class=\"usa-sr-only\" for=\"search-field\"> Search </label> <input class=\"usa-input\" id=\"search-field-mobile-navigation\" name=\"search\" placeholder=\"Search NCBI\" type=\"search\"/> <button class=\"usa-button\" type=\"submit\"> <img alt=\"Search\" class=\"usa-search__submit-icon\" src=\"data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg==\"/> </button> </form> <div class=\"ncbi-nav__mobile-login-menu ncbi--hide-at-desktop\" hidden=\"\"> <p class=\"ncbi-nav__mobile-login-menu-status\"> Logged in as: <strong class=\"ncbi-nav__mobile-login-menu-email\"> </strong> </p> <ul class=\"usa-nav__primary usa-accordion\"> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/\"> Dashboard </a> </li> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/\"> Publications </a> </li> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/account/settings/\"> Account settings </a> </li> </ul> </div> <button class=\"usa-button ncbi-nav__mobile-login-button ncbi--hide-at-desktop\" type=\"button\"> Log in </button> </nav> </header> <section aria-label=\"PMC Header with search box\" class=\"pmc-header pmc-header--basic\"> <div class=\"pmc-nav-container\"> <div class=\"pmc-header__bar\"> <div class=\"pmc-header__logo\"> <a aria-label=\"PMC Home\" href=\"/\" title=\"Home\"> </a> </div> <button aria-label=\"Open search\" class=\"usa-button usa-button--unstyled pmc-header__search__button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 pmc-icon__open\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#search\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 pmc-icon__close\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#close\"> </use> </svg> </button> </div> <div class=\"pmc-header__search\"> <form autocomplete=\"off\" class=\"usa-search usa-search--extra usa-search--article-right-column pmc-header__search__form\" role=\"search\"> <label class=\"usa-sr-only\" for=\"pmc-search\"> Search PMC Full-Text Archive </label> <span class=\"autoComplete_wrapper flex-1\"> <input aria-autocomplete=\"both\" aria-controls=\"autoComplete_list_1\" aria-expanded=\"false\" aria-haspopup=\"true\" aria-owns=\"autoComplete_list_1\" class=\"usa-input width-full maxw-none\" id=\"pmc-search\" name=\"term\" placeholder=\"Search PMC Full-Text Archive\" required=\"required\" role=\"combobox\" type=\"search\"/> <ul aria-label=\"Suggestions\" hidden=\"\" id=\"autoComplete_list_1\" role=\"listbox\"> </ul> </span> <button class=\"usa-button\" formaction=\"https://www.ncbi.nlm.nih.gov/pmc/\" type=\"submit\"> <span class=\"usa-search__submit-text\"> Search in PMC </span> <img alt=\"Search\" class=\"usa-search__submit-icon\" src=\"/static/img/usa-icons-bg/search--white.svg\"/> </button> </form> <ul class=\"pmc-header__search__menu\"> <li> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/pmc/advanced/\"> Advanced Search </a> </li> <li> <a class=\"usa-link\" href=\"/journals/\"> Journal List </a> </li> <li> <a class=\"usa-link\" href=\"/about/userguide/\"> User Guide </a> </li> </ul> </div> </div> </section> <div class=\"usa-section padding-top-0 desktop:padding-top-6 pmc-article-section\"> <div aria-label=\"Actions bar\" class=\"grid-container pmc-actions-bar is-not-intersecting\" role=\"complementary\"> <div class=\"grid-row\"> <div class=\"grid-col-fill display-flex\"> <div class=\"display-flex\"> <ul class=\"usa-list usa-list--unstyled usa-list--horizontal\"> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex mob\"> <button aria-label=\"Open resources\" class=\"usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#more_vert\"> </use> </svg> </button> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex mob\"> <span class=\"usa-tooltip\"> <a aria-label=\"View on publisher site\" class=\"usa-link display-flex usa-tooltip__trigger\" href=\"https://doi.org/10.1158/2767-9764.CRC-24-0113\" rel=\"noreferrer noopener\" role=\"button\" tabindex=\"0\" target=\"_blank\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#launch\"> </use> </svg> </a> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> View on publisher site </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <a aria-label=\"Download PDF\" class=\"usa-link display-flex usa-tooltip__trigger\" href=\"pdf/crc-24-0113.pdf\" role=\"button\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#file_download\"> </use> </svg> </a> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Download PDF </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <button aria-label=\"Save article in MyNCBI collections.\" class=\"usa-button usa-button--unstyled collections-dialog-trigger collections-button display-flex collections-button-empty usa-tooltip__trigger\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-full\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-full.svg#icon\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-empty\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-empty.svg#icon\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Add to Collections </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <button aria-label=\"Open dialog with citation text in different styles\" class=\"usa-button usa-button--unstyled citation-dialog-trigger display-flex usa-tooltip__trigger\" role=\"button\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-empty\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#format_quote\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Cite </span> </span> </li> <li class=\"pmc-permalink display-flex\"> <span class=\"usa-tooltip\"> <button aria-expanded=\"false\" aria-haspopup=\"true\" aria-label=\"Show article permalink\" class=\"usa-button usa-button--unstyled display-flex usa-tooltip__trigger\" tabindex=\"0\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#share\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Permalink </span> </span> <div class=\"pmc-permalink__dropdown\" hidden=\"\"> <div class=\"pmc-permalink__dropdown__container\"> <h2 class=\"usa-modal__heading margin-top-0 margin-bottom-2\"> PERMALINK </h2> <div class=\"pmc-permalink__dropdown__content\"> <input aria-label=\"Article permalink\" class=\"usa-input\" type=\"text\" value=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11320025/\"/> <button aria-expanded=\"false\" class=\"usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0\" title=\"Copy article permalink\"> <svg aria-hidden=\"true\" class=\"usa-icon\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#content_copy\"> </use> </svg> <span class=\"margin-left-1\"> Copy </span> </button> </div> </div> </div> </li> </ul> </div> <button aria-label=\"Open article navigation\" class=\"usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#list\"> </use> </svg> </button> </div> </div> </div> <div class=\"grid-container desktop:padding-left-6\"> <div class=\"grid-row grid-gap\" id=\"article-container\"> <div class=\"grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content\"> <div class=\"grid-container padding-left-0 padding-right-0\"> <div class=\"grid-row desktop:margin-left-neg-6\"> <div class=\"grid-col-12\"> <div aria-label=\"Disclaimer note\" class=\"pmc-layout__disclaimer\" role=\"complementary\"> As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. <br/> Learn more: <a class=\"usa-link\" href=\"/about/disclaimer/\"> PMC Disclaimer </a> | <a class=\"usa-link\" href=\"/about/copyright/\"> PMC Copyright Notice </a> </div> </div> </div> <div class=\"grid-row pmc-wm desktop:margin-left-neg-6\"> <main class=\"usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0\" id=\"main-content\"> <section aria-label=\"Journal banner\" class=\"pmc-journal-banner text-center line-height-none\"> <img alt=\"Cancer Research Communications logo\" height=\"75\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-crc.png\" usemap=\"#pmc-banner-imagemap\" width=\"500\"/> <map name=\"pmc-banner-imagemap\"> <area alt=\"Link to Cancer Research Communications\" href=\"https://aacrjournals.org/cancerrescommun\" rel=\"noopener noreferrer\" shape=\"default\" target=\"_blank\" title=\"Link to Cancer Research Communications\"/> </map> </section> <article lang=\"en\"> <section aria-label=\"Article citation and metadata\"> <section class=\"pmc-layout__citation font-secondary font-xs\"> <div> <div class=\"display-inline-block\"> <button aria-controls=\"journal_context_menu\" aria-expanded=\"false\" class=\"cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary\" type=\"button\"> Cancer Res Commun </button> </div> . 2024 Aug 13;4(8):2058\u20132074. doi: <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1158/2767-9764.CRC-24-0113\" rel=\"noopener noreferrer\" target=\"_blank\"> 10.1158/2767-9764.CRC-24-0113 </a> </div> <nav hidden=\"hidden\" id=\"journal_context_menu\"> <ul class=\"menu-list font-family-ui\" role=\"menu\"> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/pmc/?term=%22Cancer%20Res%20Commun%22%5Bjour%5D\" role=\"menuitem\"> Search in PMC </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Cancer%20Res%20Commun%22%5Bjour%5D\" lang=\"en\" role=\"menuitem\"> Search in PubMed </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cancer%20Res%20Commun%22%5BTitle%20Abbreviation%5D\" role=\"menuitem\"> View in NLM Catalog </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"?term=%22Cancer%20Res%20Commun%22%5Bjour%5D\" role=\"menuitem\"> Add to search </a> </li> </ul> </nav> </section> <section class=\"front-matter\"> <div class=\"ameta p font-secondary font-xs\"> <hgroup> <h1> mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <em> PIK3CA </em> -Altered Tumors </h1> </hgroup> <div class=\"cg p\"> <a aria-describedby=\"id1\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Sobsey%20CA%22%5BAuthor%5D\"> <span class=\"name western\"> Constance A Sobsey </span> </a> <div hidden=\"hidden\" id=\"id1\"> <h3> <span class=\"name western\"> Constance A Sobsey </span> </h3> <div class=\"p\"> <sup> 1 </sup> Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada. </div> <div class=\"p\"> <sup> 2 </sup> Division of Experimental Medicine, McGill University, Montreal, QC, Canada. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Sobsey%20CA%22%5BAuthor%5D\"> <span class=\"name western\"> Constance A Sobsey </span> </a> </div> </div> <sup> 1, </sup> <sup> 2 </sup> , <a aria-describedby=\"id2\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Froehlich%20BC%22%5BAuthor%5D\"> <span class=\"name western\"> Bjoern C Froehlich </span> </a> <div hidden=\"hidden\" id=\"id2\"> <h3> <span class=\"name western\"> Bjoern C Froehlich </span> </h3> <div class=\"p\"> <sup> 3 </sup> University of Victoria-Genome British Columbia Proteomics Centre, University of Victoria, Victoria, BC, Canada. </div> <div class=\"p\"> <sup> 4 </sup> Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Froehlich%20BC%22%5BAuthor%5D\"> <span class=\"name western\"> Bjoern C Froehlich </span> </a> </div> </div> <sup> 3, </sup> <sup> 4 </sup> , <a aria-describedby=\"id3\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Mitsa%20G%22%5BAuthor%5D\"> <span class=\"name western\"> Georgia Mitsa </span> </a> <div hidden=\"hidden\" id=\"id3\"> <h3> <span class=\"name western\"> Georgia Mitsa </span> </h3> <div class=\"p\"> <sup> 1 </sup> Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada. </div> <div class=\"p\"> <sup> 2 </sup> Division of Experimental Medicine, McGill University, Montreal, QC, Canada. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Mitsa%20G%22%5BAuthor%5D\"> <span class=\"name western\"> Georgia Mitsa </span> </a> </div> </div> <sup> 1, </sup> <sup> 2 </sup> , <a aria-describedby=\"id4\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Ibrahim%20S%22%5BAuthor%5D\"> <span class=\"name western\"> Sahar Ibrahim </span> </a> <div hidden=\"hidden\" id=\"id4\"> <h3> <span class=\"name western\"> Sahar Ibrahim </span> </h3> <div class=\"p\"> <sup> 1 </sup> Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada. </div> <div class=\"p\"> <sup> 2 </sup> Division of Experimental Medicine, McGill University, Montreal, QC, Canada. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Ibrahim%20S%22%5BAuthor%5D\"> <span class=\"name western\"> Sahar Ibrahim </span> </a> </div> </div> <sup> 1, </sup> <sup> 2 </sup> , <a aria-describedby=\"id5\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Popp%20R%22%5BAuthor%5D\"> <span class=\"name western\"> Robert Popp </span> </a> <div hidden=\"hidden\" id=\"id5\"> <h3> <span class=\"name western\"> Robert Popp </span> </h3> <div class=\"p\"> <sup> 5 </sup> MRM Proteomics Inc., Montreal, QC, Canada. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Popp%20R%22%5BAuthor%5D\"> <span class=\"name western\"> Robert Popp </span> </a> </div> </div> <sup> 5 </sup> , <a aria-describedby=\"id6\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zahedi%20RP%22%5BAuthor%5D\"> <span class=\"name western\"> Rene P Zahedi </span> </a> <div hidden=\"hidden\" id=\"id6\"> <h3> <span class=\"name western\"> Rene P Zahedi </span> </h3> <div class=\"p\"> <sup> 1 </sup> Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada. </div> <div class=\"p\"> <sup> 6 </sup> Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada. </div> <div class=\"p\"> <sup> 7 </sup> Manitoba Centre for Proteomics and Systems Biology, Winnipeg, MB, Canada. </div> <div class=\"p\"> <sup> 8 </sup> Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB, Canada. </div> <div class=\"p\"> <sup> 9 </sup> CancerCare Manitoba Research Institute, Winnipeg, MB, Canada. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zahedi%20RP%22%5BAuthor%5D\"> <span class=\"name western\"> Rene P Zahedi </span> </a> </div> </div> <sup> 1, </sup> <sup> 6, </sup> <sup> 7, </sup> <sup> 8, </sup> <sup> 9 </sup> , <a aria-describedby=\"id7\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22de%20Bruin%20EC%22%5BAuthor%5D\"> <span class=\"name western\"> Elza C de Bruin </span> </a> <div hidden=\"hidden\" id=\"id7\"> <h3> <span class=\"name western\"> Elza C de Bruin </span> </h3> <div class=\"p\"> <sup> 10 </sup> Oncology R&amp;D, AstraZeneca, Cambridge, United Kingdom. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22de%20Bruin%20EC%22%5BAuthor%5D\"> <span class=\"name western\"> Elza C de Bruin </span> </a> </div> </div> <sup> 10 </sup> , <a aria-describedby=\"id8\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Borchers%20CH%22%5BAuthor%5D\"> <span class=\"name western\"> Christoph H Borchers </span> </a> <div hidden=\"hidden\" id=\"id8\"> <h3> <span class=\"name western\"> Christoph H Borchers </span> </h3> <div class=\"p\"> <sup> 1 </sup> Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada. </div> <div class=\"p\"> <sup> 2 </sup> Division of Experimental Medicine, McGill University, Montreal, QC, Canada. </div> <div class=\"p\"> <sup> 11 </sup> Gerald Bronfman Department of Oncology, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada. </div> <div class=\"p\"> <sup> 12 </sup> Department of Pathology, McGill University, Montreal, QC, Canada. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Borchers%20CH%22%5BAuthor%5D\"> <span class=\"name western\"> Christoph H Borchers </span> </a> </div> </div> <sup> 1, </sup> <sup> 2, </sup> <sup> 11, </sup> <sup> 12 </sup> , <a aria-describedby=\"id9\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Batist%20G%22%5BAuthor%5D\"> <span class=\"name western\"> Gerald Batist </span> </a> <div hidden=\"hidden\" id=\"id9\"> <h3> <span class=\"name western\"> Gerald Batist </span> </h3> <div class=\"p\"> <sup> 13 </sup> Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada. </div> <div class=\"p\"> <sup> 14 </sup> McGill Centre for Translational Research in Cancer, Lady Davis Institute, Montreal, QC, Canada. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Batist%20G%22%5BAuthor%5D\"> <span class=\"name western\"> Gerald Batist </span> </a> </div> </div> <sup> 13, </sup> <sup> 14, </sup> <sup> * </sup> </div> <ul class=\"d-buttons inline-list\"> <li> <button aria-controls=\"aip_a\" aria-expanded=\"false\" class=\"d-button\"> Author information </button> </li> <li> <button aria-controls=\"anp_a\" aria-expanded=\"false\" class=\"d-button\"> Article notes </button> </li> <li> <button aria-controls=\"clp_a\" aria-expanded=\"false\" class=\"d-button\"> Copyright and License information </button> </li> </ul> <div class=\"d-panels font-secondary-light\"> <div class=\"d-panel p\" id=\"aip_a\"> <div class=\"p\" id=\"aff1\"> <sup> 1 </sup> Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada. </div> <div id=\"aff2\"> <sup> 2 </sup> Division of Experimental Medicine, McGill University, Montreal, QC, Canada. </div> <div id=\"aff3\"> <sup> 3 </sup> University of Victoria-Genome British Columbia Proteomics Centre, University of Victoria, Victoria, BC, Canada. </div> <div id=\"aff4\"> <sup> 4 </sup> Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada. </div> <div id=\"aff5\"> <sup> 5 </sup> MRM Proteomics Inc., Montreal, QC, Canada. </div> <div id=\"aff6\"> <sup> 6 </sup> Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada. </div> <div id=\"aff7\"> <sup> 7 </sup> Manitoba Centre for Proteomics and Systems Biology, Winnipeg, MB, Canada. </div> <div id=\"aff8\"> <sup> 8 </sup> Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB, Canada. </div> <div id=\"aff9\"> <sup> 9 </sup> CancerCare Manitoba Research Institute, Winnipeg, MB, Canada. </div> <div id=\"aff10\"> <sup> 10 </sup> Oncology R&amp;D, AstraZeneca, Cambridge, United Kingdom. </div> <div id=\"aff11\"> <sup> 11 </sup> Gerald Bronfman Department of Oncology, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada. </div> <div id=\"aff12\"> <sup> 12 </sup> Department of Pathology, McGill University, Montreal, QC, Canada. </div> <div id=\"aff13\"> <sup> 13 </sup> Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada. </div> <div id=\"aff14\"> <sup> 14 </sup> McGill Centre for Translational Research in Cancer, Lady Davis Institute, Montreal, QC, Canada. </div> <div class=\"author-notes p\"> <div class=\"fn\" id=\"cor1\"> <sup> * </sup> <p class=\"display-inline\"> <strong> Corresponding Author: </strong> Gerald Batist, Jewish General Hospital, 3755 Cote St Catherine Road, Montreal, QC H3T 1E2, Canada. E-mail: <span> Gerald.batist@mcgill.ca </span> </p> </div> </div> </div> <div class=\"d-panel p\" id=\"anp_a\"> <div class=\"notes p\"> <section class=\"history\" id=\"historyarticle-meta1\"> <p> Received 2024 Mar 28; Revised 2024 May 12; Accepted 2024 Jun 28; Collection date 2024 Aug. </p> </section> </div> </div> <div class=\"d-panel p\" id=\"clp_a\"> <div> \u00a92024 The Authors; Published by the American Association for Cancer Research </div> <p> This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. </p> <div class=\"p\"> <a class=\"usa-link\" href=\"/about/copyright/\"> PMC Copyright notice </a> </div> </div> </div> <div> PMCID: PMC11320025 PMID: <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/38954770/\"> 38954770 </a> </div> </div> </section> </section> <section aria-label=\"Article content\"> <section class=\"body main-article-body\"> <section class=\"abstract\" id=\"abstract1\"> <h2> <a class=\"usa-anchor\" id=\"abstract1-anchor\"> </a> Abstract </h2> <p> Capivasertib is a potent selective inhibitor of AKT. It was recently FDA approved in combination with fulvestrant to treat HR <sup> + </sup> , HER2-negative breast cancers with certain genetic alteration(s) activating the PI3K pathway. In phase I trials, heavily pretreated patients with tumors selected for activating PI3K pathway mutations treated with capivasertib monotherapy demonstrated objective response rates of &lt;30%. We investigated the proteomic profile associated with capivasertib response in genetically preselected patients and cancer cell lines. We analyzed samples from 16 <em> PIK3CA </em> -mutated patient tumors collected prior to capivasertib monotherapy in the phase I trial. PI3K pathway proteins were precisely quantified with immuno-Matrix-Assisted Laser Desorption/Ionization-mass spectrometry (iMALDI-MS). Global proteomic profiles were also obtained. Patients were classified according to response to capivasertib monotherapy: \u201cclinical benefit (CB)\u201d (\u226512 weeks without progression, <em> n </em> = 7) or \u201cno clinical benefit (NCB)\u201d (progression in &lt;12 weeks, <em> n </em> = 9). Proteins that differed between the patient groups were subsequently quantified in <em> AKT1- or PIK3CA </em> -altered breast cancer cell lines with varying capivasertib sensitivity. The measured concentrations of AKT1 and AKT2 varied among the <em> PIK3CA </em> -mutated tumors but did not differ between the CB and NCB groups. However, analysis of the global proteome data showed that translational activity was higher in tumors of the NCB vs. CB group. When reproducibly quantified by validated LC-MRM-MS assays, the same proteins of interest similarly distinguished between capivasertib-sensitive versus -resistant cell lines. The results provide further evidence that increased mTORC1-driven translation functions as a mechanism of resistance to capivasertib monotherapy. Protein concentrations may offer additional insights for patient selection for capivasertib, even among genetically preselected patients. </p> <section id=\"sec1\"> <h3 class=\"pmc_sec_title\"> Significance: </h3> <p> Capivasertib\u2019s first-in-class FDA approval demonstrates its promise, yet there remains an opportunity to optimize its use. Our results provide new evidence that proteomics can stratify genetically preselected patients on clinical benefit. Characterization of the same profile in cell lines furnishes additional validation. Among <em> PIK3CA </em> -altered tumors, increased mTORC1-driven translation appears to confer intrinsic resistance. Assessing mTORC1 activation could therefore prove a useful complement to the existing genetic selection strategy for capivasertib. </p> </section> </section> <section id=\"s1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"s1-anchor\"> </a> Introduction </h2> <p> The PI3K/AKT/mTOR signaling pathway has an established role in tumor cell proliferation, is mutated in more than 50% of breast cancers ( <a aria-describedby=\"bib1\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib1\"> 1 </a> ), and is the target of many new therapeutic agents ( <a aria-describedby=\"bib2\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib2\"> 2 </a> ). Although direct mutations of AKT are comparatively rare, overexpression and overactivation of AKT are key factors in cancer progression. In response to PI3K pathway activation, phospho-AKT promotes downstream oncogenic functions including cell growth, cell survival, and metabolic changes ( <a aria-describedby=\"bib3\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib3\"> 3 </a> ). Capivasertib (AZD5363, Truqap) competitively interacts with the ATP binding site of all three AKT isoforms (AKT1/2/3) and inhibits AKT\u2019s catalytic activity with high potency and higher selectivity than previously developed compounds, resulting in the arrest of tumor cell growth ( <a aria-describedby=\"bib4\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib4\"> 4 </a> ). </p> <p> Capivasertib in combination with fulvestrant was FDA approved in November 2023 for the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, with one or more confirmed genetic alterations associated with PI3K pathway activation ( <a aria-describedby=\"bib5\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib5\"> 5 </a> ) <em> . </em> FoundationOne was approved as a companion diagnostic assay for the associated genetic markers, which include mutations, copy-number variation, and other alterations, in <em> PIK3CA </em> , <em> AKT1 </em> , or <em> PTEN </em> ( <a aria-describedby=\"bib5\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib5\"> 5 </a> ). The eligible cohort is currently limited to adults who progressed on endocrine-based therapy in the metastatic setting or who had recurrence during or within 12 months of completing adjuvant therapy. The approval of capivasertib plus fulvestrant therapy is based on results of the CAPItello-291 phase III trial, which demonstrated a dramatically reduced hazard ratio (HR) of 0.51 on the primary endpoint of progression-free survival (PFS) for combination therapy versus fulvestrant alone in patients with PI3K-altered tumors ( <a aria-describedby=\"bib5\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib5\"> 5 </a> ). However, an exploratory analysis of patients whose tumors did not harbor identifiable PI3K pathway alterations found a possible benefit for the addition of capivasertib in this cohort as well, as indicated by a HR of 0.61 to 1.02 [95% confidence interval (CI)] after excluding patients with unknown next-generation sequencing results. </p> <p> Previous clinical trials have delivered varying results with respect to the power and necessity of genetic biomarkers for capivasertib. In phase I trials, heavily pretreated patients, patients selected for their tumors' activating <em> PIK3CA </em> and <em> AKT1 </em> mutations had objective response rates (ORR) of 4% to 29% to capivasertib monotherapy ( <a aria-describedby=\"bib6\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib6\"> 6 </a> \u2013 <a aria-describedby=\"bib8\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib8\"> 8 </a> ). This represents a clinically meaningful response rate in a population of patients with advanced solid tumors who had previously progressed on standard therapies. However, higher clinical activity might be expected in a population carefully selected for a targeted agent. The FAKTION phase II trial ( <em> n </em> = 140), which evaluated capivasertib plus fulvestrant in aromatase inhibitor-resistant estrogen receptor (ER)-positive breast cancer, initially found no effect of mutations on the response rate to combination therapy ( <a aria-describedby=\"bib9\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib9\"> 9 </a> ), whereas a subsequent updated analysis ( <em> n </em> = 185) found that the benefit was greater in patients with activating mutations ( <a aria-describedby=\"bib10\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib10\"> 10 </a> ). In CAPItello-291, the clinical benefit (CB) rate for combination therapy of 56% among the subset of patients with PI3K-altered tumors ( <em> n </em> = 289) was similar to the rate of 51% across the overall population ( <em> n </em> = 708) enrolled in the study ( <a aria-describedby=\"bib5\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib5\"> 5 </a> ). </p> <p> While the recent FDA approval doubtlessly weighed the results of all of these studies in the decision to guide patient selection with gene-based assays, we believe that this data\u2014together with the fact that capivasertib is first-in-class\u2014means that, like many new drugs, further investigation is merited into biomarkers to help optimize the effective use of capivasertib in clinical practice. Direct measurement of the proteome has shown unique potential for identifying and verifying active cancer-driving alterations that closely correspond to a tumors\u2019 treatment sensitivity or resistance ( <a aria-describedby=\"bib11\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib11\"> 11 </a> , <a aria-describedby=\"bib12\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib12\"> 12 </a> ). To evaluate the utility of proteomics for predicting treatment response to capivasertib, we utilized modern mass spectrometry\u2013based methods to directly analyze the protein content of formalin-fixed, paraffin-embedded (FFPE) tumor tissues from patients enrolled in a phase I study of capivasertib\u2019s antitumor activity. To further verify an association between the observed proteomic profile and capivasertib response, we applied corresponding targeted assays, validated in accordance with the NCI\u2019s Clinical Proteomics Tumor Analysis Consortium (CPTAC) guidelines, to precisely quantify proteins of interest in analogous <em> PIK3CA </em> -altered breast cancer cell lines with varying sensitivities to capivasertib. </p> </section> <section id=\"s2\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"s2-anchor\"> </a> Materials and Methods </h2> <p> Full descriptions of all methods are provided in the Supplemental Materials. </p> <section id=\"s2-1\"> <h3 class=\"pmc_sec_title\"> Patient tumor samples </h3> <p> The study was conducted in accordance with the Declaration of Helsinki and approved by the Research Ethics Committee of the Jewish General Hospital (Project #2018-663 17-004, approved March 03, 2017) in Montreal, Quebec, Canada. Anonymized patient data and samples were obtained under site-specific Research Ethics Board approval as part of AstraZeneca\u2019s registered international multicenter clinical trial of AZD5363 ( <a class=\"usa-link\" href=\"https://clinicaltrials.gov/ct2/show/NCT01226316\" rel=\"noopener noreferrer\" target=\"_blank\"> NCT01226316 </a> , posted October 22, 2010; ref. <a aria-describedby=\"bib6\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib6\"> 6 </a> ). Written informed consent was obtained from all participants. De-identified samples and clinical data were provided for analysis under the conditions of a legal agreement between AstraZeneca, McGill University, University of Victoria, and the funders, in accordance with the patient consent form. </p> <p> The sample set was drawn from patients with breast cancer whose tumor pathology was either ER positive (ER <sup> + </sup> ) or HER2-positive (HER2 <sup> + </sup> ), or patients with gynecological (ovarian, cervical, or endometrial) cancers for whom no standard therapy was effective. For this cohort, eligibility was restricted to patients whose tumors contained known activating <em> PIK3CA </em> mutation(s) detected during screening. Tumor samples obtained at the time of screening were stored at ambient temperature as slide-mounted 4-\u00b5m-thick FFPE tumor tissue slices. </p> <p> The enrolled patients received capivasertib 480 mg twice daily for 4 days followed by 3 days off, repeated in 21-day cycles. Tumor volume was measured according to RECIST v1.1 criteria within 28 days of the start of treatment and at specified timepoints after the start of treatment (i.e., weeks 6, 12, 18, 24, etc.). Target lesion response was categorized into complete response (CR), partial response (PR, \u226530% decrease), stable disease (SD, volume \u00b1 &lt;30%), or progressive disease (PD, \u226530% increase; ref. <a aria-describedby=\"bib6\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib6\"> 6 </a> ). Treatment was continued as tolerated, until evidence of disease progression. Standardized, anonymized response data were used to classify patient drug response based on PFS. CB was defined as PFS observed for a minimum of 12 weeks after starting capivasertib. \u201cNo CB\u201d (NCB) was defined as less than 12 weeks of observed PFS while receiving capivasertib. </p> </section> <section id=\"s2-2\"> <h3 class=\"pmc_sec_title\"> Cell line samples </h3> <p> Well-characterized hormone-receptor positive, <em> AKT1 </em> - or <em> PIK3CA </em> -altered breast cancer cell lines were selected for analysis. HCC-1428 (RRID:CVCL_1252) was purchased from ATCC (CRL-2327, via Cedarlane, Feb 2022). EFM-19 (RRID:CVCL_0253) was purchased DSMZ (ACC 231, July 2022). ZR-75-30 (RRID:CVCL_1661) and MCF-7 (RRID:CVCL_0031) were gifts from the laboratory of Dr. Mark Basik at the Segal Cancer Centre (received May 2022). Cell lines underwent short tandem repeat DNA profiling and mycoplasma detection/elimination prior to the beginning of the experiments, which were conducted June to November 2022. All cell lines were cultured in RPMI-1640 with 10% or 15% FBS, according to manufacturer directions, with 1% P/S, for fewer than 8 passages. Samples of each cell line were collected prior to capivasertib exposure, washed with PBS, and stored at \u221280\u00b0C until analysis. Each cell line was tested for sensitivity to capivasertib using a standard alamarBlue cytotoxicity assay, based on at least three independent replicates. </p> </section> <section id=\"s2-3\"> <h3 class=\"pmc_sec_title\"> Protein extraction, digestion, and immuno-Matrix-Assisted Laser Desorption/Ionization mass spectrometry (iMALDI-MS) </h3> <p> Tumor samples were processed and analyzed using a multistep workflow (Supplementary Methods S1), beginning with xylene deparaffinization and ethanol rehydration. Samples were then extracted by high-temperature incubation and sonication. The concentration of total protein in each sample was quantified by Pierce bicinchoninic acid protein assay kit with a ThermoFisher MultiSkan Go spectrophotometer. </p> <p> Quantitation of AKT by immuno-matrix-assisted laser desorption/ionization (iMALDI)-MS was performed as previously described ( <a aria-describedby=\"bib13\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib13\"> 13 </a> ). Diluted sample aliquots containing 10 \u00b5g of total protein were prepared in an automated fashion on an Agilent Bravo Liquid Handling Robot. The calibration curve was prepared by spiking known quantities (0\u201320 fmol) of unlabeled standard peptide into 10 \u00b5g of bovine serum albumin. Each tumor or calibration sample was denatured with sodium deoxycholate (DOC), reduced with tris(2-carboxyethyl)phosphine (TCEP), alkylated with iodoacetamide (IAA), and quenched with dithiothreitol (DTT). Digestion was performed with tosyl phenylalanyl chloromethyl ketone (TCPK)-treated trypsin (substrate-to-enzyme ratio of 2:1, 1 hour, 37\u00b0C), prior to quenching with tosyllysine chloromethylketone (TLCK). A phosphatase-based phosphopeptide quantitation (PPQ) method, as described in Domanski and colleagues ( <a aria-describedby=\"bib14\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib14\"> 14 </a> ), was performed by incubating aliquots with or without alkaline phosphatase (1U/\u00b5g total protein, 2 hours, 37\u00b0C). Stable isotope-labeled internal standard peptides were added to each digested sample. </p> <p> Immunoenrichment was achieved by tumbling samples overnight at 4\u00b0C with antipeptide antibodies (Signatope GmbH) coupled to magnetic beads. The AKT-depleted supernatant from this step was retained; a portion was reserved for global proteome analysis by nano-LC-Orbitrap MS. The remainder was sequentially enriched using antipeptide antibodies for PTEN and PI3K p110\u03b1 to enable quantitation via our previously validated iMALDI method ( <a aria-describedby=\"bib15\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib15\"> 15 </a> ). Beads were washed prior to spotting on a MALDI target. \u03b1-Cyano-4-hydroxycinnamic acid (HCCA) MALDI matrix was applied to the dried spots, which were stored at room temperature until analysis. </p> <p> Mass spectra were acquired on a Bruker Microflex LRF benchtop MALDI-TOF-MS (RRID:SCR_018696). Data analysis was performed in FlexAnalysis 3.4 with Savitsky-Golay smoothing, baseline subtraction, and automated peak picking. Calibration curves were generated using a linear regression with a 1/x <sup> 2 </sup> weighting. Assay performance was confirmed with quality control samples (QC samples; Supplementary Validation Data S1). </p> </section> <section id=\"s2-4\"> <h3 class=\"pmc_sec_title\"> Nano-LC-Orbitrap MS analysis, protein identification and quantification </h3> <p> A 2-\u00b5L aliquot of the AKT-depleted supernatant from each sample\u2019s immunoenrichment, corresponding to 117.5 ng of total protein digest, was reserved for label-free quantitation of the global proteome. Samples were prepared using custom StageTips for desalting before drying under vacuum and resuspension in 0.1% formic acid for injection. </p> <p> Online liquid chromatography was performed on an Easy-nLC 1200 equipped with a precolumn (particle size, 3 \u00b5m; 2 cm \u00d7 75 \u00b5m inner diameter) and a nanoscale main analytical column (particle size, 2 \u00b5m; 25 cm \u00d7 75 \u00b5m inner diameter), both AcclaimPepMap100 C18 (ThermoFisher Scientific). Elution was performed over a 50-minute gradient (flow rate, 300 nL/minutes; 20\u00b0C; mobile phase A: 0.1% formic acid; mobile phase B: 84% acetonitrile, 0.1% formic acid). </p> <p> Mass spectra were acquired on a Q-Exactive Plus MS with a Nanospray Flex ion source (RRID:SCR_020556, ThermoFisher Scientific). Using a data-dependent acquisition (DDA) method, the 15 most abundant precursor ions (charge states: 2+ to 4+) were selected for MS/MS fragmentation (dynamic exclusion, 40 seconds). Full scan MS were acquired for the mass range from m/z 350 to m/z 1,500 (resolution, 70,000; AGC target, 1 \u00d7 10 <sup> 6 </sup> ; max injection time, 50 ms). MS2 spectra were acquired following HCD fragmentation (normalized CE, 28), with an isolation width of 1.2 Da (resolution, 17,500; AGC target, 2 \u00d7 10 <sup> 4 </sup> ; max injection time, 64 ms). </p> <p> MS raw global proteome data were processed using Proteome Discoverer 2.4 (RRID:SCR_014477, Thermo Scientific). Database searches were performed using SequestHT (RRID:SCR_000286) and a human Swiss-Prot database (RRID:SCR_021164, January 2019; 20,414 target entries), assuming a maximum of 1 missed tryptic cleavage. Mass tolerances were 10 ppm for precursor ions and 0.02 Da for product ions. Scaled, normalized, abundances were exported to Microsoft Excel (RRID:SCR_016137), and filtered for protein IDs with \u22652 unique peptides. </p> </section> <section id=\"s2-5\"> <h3 class=\"pmc_sec_title\"> LC-MRM-MS assays </h3> <p> Targeted multiplexed UPLC-MRM-MS assays were developed and optimized for 54 proteins of interest using synthetic proteotypic peptides for calibration and corresponding stable isotope-labeled (SIS) peptides as internal standards for quantitation (Sobsey and colleagues, submitted). Assays were characterized in accordance with the CPTAC guidelines ( <a aria-describedby=\"bib16\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib16\"> 16 </a> ). </p> <p> Cell line samples underwent extraction and total protein quantitation using methods similar to those used on the deparaffinized patient tumor samples. Aliquots of 80 \u00b5g of total protein were manually prepared for in-solution digestion by denaturation with DOC, reduction with TCEP, alkylation with IAA, and quenching with DTT. Tryptic digestion was performed at a substrate-to-enzyme ratio of 20:1 (Worthington, TCPK-treated, 17 hours, 37\u00b0C), prior to quenching on ice, and spiking with SIS peptides. Solid Phase Extraction (Oasis SPE HLB 1 cc cartridges, 10 mg sorbent) was performed according to manufacturer directions on a vacuum manifold. Eluates were dried under vacuum and reconstituted in H <sub> 2 </sub> O, 0.1% formic acid for injection. The calibration curve was prepared by adding known equimolar quantities (0\u2013100 fmol on-column) of 54 unlabeled synthetic peptides into digested BSA spiked with SIS peptide mix. A previously quantified pooled cell lysate sample was repeatedly analyzed as a quality control. </p> <p> Samples and calibration standards were analyzed via 10 \u03bcL injections (20 \u00b5g total protein digest on-column) on an Agilent 1290 Infinity liquid chromatography system (RRID:SCR_019375) with a Zorbax Eclipse plus C18 column (RRHD; particle size, 1.8 \u00b5m; internal diameter, 2.1 \u00d7 15 mm; 50\u00b0C; flow rate, 0.35 mL/minutes) coupled to a 6495B triple quadrupole mass spectrometer (Agilent Technologies, Santa Clara, CA). Elution was performed over a 46-minute gradient (B: 2%\u201380%; mobile phase A: H <sub> 2 </sub> O, 0.1% formic acid, mobile phase B: acetonitrile, 0.1% formic acid). Mass spectra were acquired in positive ion mode using a scheduled MRM-MS method targeting \u22653 transition pairs per peptide. Data were processed in Skyline (RRID:SCR_014080) for peak integration and quantitation. </p> </section> <section id=\"s2-6\"> <h3 class=\"pmc_sec_title\"> Data analysis and bioinformatics </h3> <p> Descriptive statistics and protein concentration data were analyzed in Microsoft Excel (RRID:SCR_016137). Group differences were assessed using the common <em> t </em> test and nonparametric tests to address the possibility of non-normal distributions in the protein concentration data. Multivariate statistical analysis was performed using MetaboAnalyst (RRID:SCR_015539; ref. <a aria-describedby=\"bib17\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib17\"> 17 </a> ). Volcano plots, Principal Component Analysis, Partial Least Squares Discriminant Analysis, Variable Importance in the Projection (VIP) scores, heatmaps, and hierarchical clustering were generated based on normalized data. StringDB was used for network analysis, to identify clusters of related proteins, and to identify related publications ( <a aria-describedby=\"bib18\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib18\"> 18 </a> ). Cytoscape (RRID:SCR_003032) was used to visualize the regulation of proteins within the network ( <a aria-describedby=\"bib19\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib19\"> 19 </a> ). QIAGEN Ingenuity Pathway Analysis (IPA; RRID:SCR_008653) software was used to map the label-free quantification data to canonical pathways. QC analyses confirmed the integrity of the data following batch integration, normalization, and scaling of features (Supplementary Validation Data S2). </p> </section> <section id=\"s2-7\"> <h3 class=\"pmc_sec_title\"> Data availability </h3> <p> Individual participant data associated with the clinical trials sponsored by AstraZeneca can be requested by qualified researchers via the request portal, with request evaluated according to the AstraZeneca disclosure commitment ( <a class=\"usa-link usa-link--external\" href=\"https://astrazenecagroup-dt.pharmacm.com/DT/Home\" rel=\"noopener noreferrer\" target=\"_blank\"> https://astrazenecagroup-dt.pharmacm.com/DT/Home </a> ) and Responsible Data Sharing Principles. Global proteomics spectra and associated were deposited to the ProteomeXchange Consortium ( <a class=\"usa-link usa-link--external\" href=\"https://www.proteomexchange.org/\" rel=\"noopener noreferrer\" target=\"_blank\"> https://www.proteomexchange.org/ </a> ) via the PRIDE partner repository with the dataset identifier PXD052949. Samples of the polyclonal antibodies for AKT1 and AKT2 can be requested through the Segal Cancer Proteomics Centre (Montreal, QC, Canada). LC-MRM-MS assay information and validation data are publicly available in the CPTAC Assay Portal ( <a class=\"usa-link usa-link--external\" href=\"https://assays.cancer.gov/available_assays\" rel=\"noopener noreferrer\" target=\"_blank\"> https://assays.cancer.gov/available_assays </a> , IDs: 6077-6129; see Supplementary Methods S1 for links to each assay). MRM-MS assay kits including the required peptide standards and instrument files are now commercially available from MRM Proteomics Inc. (Montreal, QC, Canada). </p> </section> </section> <section id=\"s3\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"s3-anchor\"> </a> Results </h2> <p> Slide-mounted FFPE tumor samples were obtained from patients with activating <em> PIK3CA </em> mutations in their ER <sup> + </sup> or HER <sup> + </sup> breast or gynecological cancers, respectively, prior to treatment in a multicenter phase I clinical trial of capivasertib ( <a class=\"usa-link\" href=\"https://clinicaltrials.gov/ct2/show/NCT01226316\" rel=\"noopener noreferrer\" target=\"_blank\"> NCT01226316 </a> ). Twenty-three 4-\u03bcm slides, representing 16 patient tumors, yielded sufficient material (\u226525 \u03bcg total protein/slide) for the analyses. Patients were coded as \u201cCB\u201d (\u226512 weeks of PFS after treatment initiation; <em> n </em> = 7) or \u201cNCB\u201d (&lt;12 weeks PFS; <em> n </em> = 9) as described in the \u201cMethods\u201d section. As shown in <a class=\"usa-link\" href=\"#tbl1\"> Table 1 </a> , the two groups had similar overall clinical characteristics, but the CB group had a greater proportion of samples derived from metastatic sites compared to the NCB group. </p> <section class=\"tw xbox font-sm\" id=\"tbl1\"> <h3 class=\"obj_head\"> Table 1. </h3> <div class=\"caption p\"> <p> Descriptive statistics for the patient samples analyzed </p> </div> <div class=\"tbl-box p\" tabindex=\"0\"> <table class=\"content\" frame=\"hsides\" rules=\"groups\"> <thead> <tr> <th align=\"left\" colspan=\"1\" rowspan=\"2\"> </th> <th align=\"left\" colspan=\"1\" rowspan=\"1\"> Clinical Benefit (CB) </th> <th align=\"left\" colspan=\"1\" rowspan=\"1\"> No Clinical Benefit (NCB) </th> </tr> <tr> <th align=\"left\" colspan=\"1\" rowspan=\"1\"> Group ( <em> n </em> = 7) </th> <th align=\"left\" colspan=\"1\" rowspan=\"1\"> Group ( <em> n </em> = 9) </th> </tr> </thead> <tbody> <tr> <td align=\"left\" colspan=\"3\" rowspan=\"1\"> Clinical Information </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Breast ( <em> n </em> =__) </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 3 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 4 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Gynecological ( <em> n </em> =__) </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 4 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 5 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Patient weight (kg) </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 69.9 \u00b1 18.8 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 58.9 \u00b1 10.2 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Patient age (years) </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 63.0 \u00b1 10.9 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 56.7 \u00b1 9.4 </td> </tr> <tr> <td align=\"left\" colspan=\"3\" rowspan=\"1\"> WHO Performance Status </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> PS 0 ( <em> n </em> =__) </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 3 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 5 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> PS 1 ( <em> n </em> =__) </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 4 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 4 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Metastatic sites at enrollment </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 2.7 \u00b1 1.0 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 3.4 \u00b1 1.6 </td> </tr> <tr> <td align=\"left\" colspan=\"3\" rowspan=\"1\"> Previous lines of treatment </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> \u22642 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 1 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 3 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> \u22653 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 4 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 5 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Not specified </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 2 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 1 </td> </tr> <tr> <td align=\"left\" colspan=\"3\" rowspan=\"1\"> Capivasertib Response </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Adjusted progression-free survival (weeks)* </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> median: 21.1 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 5.6 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> survival (weeks)* </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> (95% CI: 13.0 to 32.3) </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> (95% CI: 5.3 to 6.1) </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Best change in tumour volume from </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> median: \u221211.9 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> median: 28.6 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> baseline (RECIST %)** </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> (95% CI: \u221252.2 to \u22128.1) </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> (95% CI: 2.3 to 35.9) </td> </tr> <tr> <td align=\"left\" colspan=\"3\" rowspan=\"1\"> Sample Characteristics </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Sample site* </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 4 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 4 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Metastatic ( <em> n </em> =__) </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 5 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 1 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Primary ( <em> n </em> =__) </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 2 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 8 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Storage time (years) </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 7.3 \u00b1 0.7 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 7.6 \u00b1 1.4 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Tissue area (mm2) </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 330.7 \u00b1 116.8 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 339.5 \u00b1 151.3 </td> </tr> <tr> <td align=\"left\" colspan=\"3\" rowspan=\"1\"> Cellularity </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Tumour cells (%) </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 62.9 \u00b1 11.6 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 65.9 \u00b1 22.4 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Necrosis (%) </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 3.9 \u00b1 3.2 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 5.0 \u00b1 2.7 </td> </tr> </tbody> </table> </div> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"table/tbl1/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <div class=\"tw-foot p\"> <div class=\"fn\" id=\"fn1\"> <p> Values are given as mean \u00b1 standard deviation unless otherwise specified. All patients were female. </p> </div> <div class=\"fn\" id=\"fn2\"> <p> *Denotes statistical significance at <em> P </em> &lt; 0.05 ( <em> t </em> test unequal variance, two-tailed), ** <em> P </em> &lt; 0.01. </p> </div> </div> </section> <section id=\"s3-1\"> <h3 class=\"pmc_sec_title\"> Tumor AKT protein concentrations do not differ between CB and NCB groups </h3> <p> Twenty-two slides representing 16 patient tumors were analyzed by iMALDI-MS. The lower limits of quantitation (LLOQ) for AKT1 and AKT2 were 0.3 and 0.6 fmol on-spot, respectively. Among the <em> PIK3CA </em> mutation-positive tumor samples with AKT data (CB <em> n </em> = 7, NCB <em> n </em> = 5), the amount of AKT present per 10 \u00b5g total protein ranged from 0.6 to 4.5 fmol for AKT1 and 0.6 to 2.0 fmol for AKT2. For tumors from which multiple slides were analyzed, the AKT concentrations showed good agreement across biological replicates, even among non-adjacent slices ( <em> R </em> <sup> 2 </sup> &gt; 0.95). Most samples did not show sufficient phosphorylation (&gt;30%) of AKT1-Ser473 or AKT2-Ser474 to be quantified by the PPQ assay, with measurable phosphorylation observed in only three tumors (Supplementary Fig. S1). Using the AKT-depleted digest from the AKT iMALDI assay, PTEN and PI3K p110\u03b1 were quantified in 14 patient tumors (CB <em> n </em> = 7, NCB <em> n </em> = 7). Within the patient sample set, the PTEN concentration values quantified by iMALDI correlated well with the PTEN histochemical scoring assessment (H-score) previously determined by immunohistochemistry ( <em> R </em> <sup> 2 </sup> = 0.86; Supplementary Fig. S2). </p> <p> Using our quantitative iMALDI-MS assay, we observed significant inter-tumor variability in the amount of AKT1 and AKT2 protein, with as much as a 4-fold difference among PIK3CA-mutated tumors. However, total AKT1, AKT2, and PTEN protein concentrations did not differ significantly between the CB and NCB groups (Wilcoxon rank test, <em> P </em> &gt; 0.05; <a class=\"usa-link\" href=\"#fig1\"> Fig. 1A </a> ). We separately quantified pAKT1-Ser473 and pAKT2-Ser474 proteins using a mass spectrometry assay with high isoform specificity. However, only three samples showed pAKT stoichiometry sufficient to be precisely quantified by the assay. </p> <figure class=\"fig xbox font-sm\" id=\"fig1\"> <h4 class=\"obj_head\"> Figure 1. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11320025_crc-24-0113_f1.jpg\" target=\"_blank\"> <img alt=\"Figure 1\" class=\"graphic zoom-in\" height=\"1951\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f07/11320025/7873c2b4662d/crc-24-0113_f1.jpg\" width=\"741\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/fig1/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> Statistical analysis of targeted and global proteome comparing protein expression in analyzed FFPE tumor tissues from the CB (green) and NCB (red) groups. <strong> A, </strong> Schematic of experimental design for phase I of the study. <strong> B, </strong> Results of targeted quantitation by iMALDI-MS. Boxplots of protein concentrations in the CB (green) vs. NCB (red) groups. Each point represents one patient tumor, averaged for multiple slides. <em> P </em> -values are given for a two-tailed <em> t </em> test. <strong> C, </strong> Heatmap of 50 selected proteins with highest differential expression between groups showing their normalized LFQ abundances across both analyzed batches. <em> n </em> = 23. Arbitrary identifiers are included for the purpose of identifying replicates from the same tumor. <strong> D, </strong> Volcano plot showing the fold change (log <sub> 2 </sub> FC) of all protein expression features vs. <em> P </em> -value (\u2212log <sub> 10 </sub> <em> P </em> ). <strong> E, </strong> PCA. Proximity of sample replicates originating from the same patients is indicated with a (dashed yellow line). <strong> F, </strong> Features ranked by VIP based on their contribution to the discrimination between the CB and NCB groups in the PLS-DA. The arrows on the right of the VIP Feature list show relative expression of that protein in the NCB group vs. the CB group. </p> </figcaption> </figure> <p> We also quantified PTEN protein since it is the dominant regulator suppressing AKT phosphorylation in <em> PIK3CA </em> -mutated cells. All three samples with &gt;30% pAKT1 or pAKT2 had low PTEN values (&lt;0.36 fmol PTEN/10 \u03bcg total protein, in Q1 of the measured values), as did one other sample with 22% pAKT1, which appeared elevated but fell below the assay\u2019s LLOQ. Nonetheless, PTEN expression levels did not differ significantly between the treatment response groups. For PI3K p110\u03b1, the large number of samples with concentrations below the lower limit of quantitation of the assay prevented a meaningful comparison between the groups. AKT2 was slightly higher in the metastatic tumors as compared to primary tumors, but the difference did not reach statistical significance ( <em> p </em> = 0.09; Supplementary Fig. S3). </p> </section> <section id=\"s3-2\"> <h3 class=\"pmc_sec_title\"> Proteins associated with oncogenic functions of AKT are differentially expressed between the CB versus NCB groups </h3> <p> Using a new serialized workflow, we acquired global proteomic data using nano-LC-MS-MS for 23 distinct tumor slides from 15 patient tumors (CB <em> n </em> = 6, NCB <em> n </em> = 9). The workflow permitted further analysis of previously analyzed samples from small aliquots of AKT-depleted supernatant, each containing approximately 107 ng of digested protein. We were able to achieve label-free quantification (LFQ) of up to 1,455 proteins at a false discovery rate of &lt;1%, with a minimum of two unique peptides per protein. A total of 578 proteins were quantified across all samples for further statistical analysis. In light of the higher proportion of samples from metastatic sites in the CB group, the proteomic profiles of metastatic versus primary tumors were compared (Supplementary Fig. S3). The differences in metastatic versus primary tumors identified by PLS-DA were attributable to known markers of metastasis, indicating that biological relationships were preserved following batch integration and data normalization. </p> <p> As shown in <a class=\"usa-link\" href=\"#fig1\"> Fig. 1 </a> , unsupervised statistical analysis of the global proteome data by hierarchical clustering and by principal component analysis (PCA) confirmed the high similarity of replicates from the same tumor. Supervised statistical analysis with Partial Least Squares\u2013Discriminant Analysis (PLS-DA) resulted in a clear separation of the CB and NCB groups, with little overlap. A total of 53 proteins had abundances that differed between the CB and the NCB group with fold-changes of \u22651.5 and Wilcoxon rank test <em> P </em> -values of \u22640.05 (Supplementary Table S1). </p> <p> Of these 53 proteins, the five proteins that were upregulated in the CB group included four immunoglobulins and serum albumin. The five proteins whose expression was higher in the CB group were serum albumin (ALB), polymeric immunoglobulin receptor (PIGR), and some immunoglobulin subunits (IGHG2, IGKC, IGKV4-1). This is aligned with previous evidence linking systemic hypoalbuminuria with reduced PFS and overall survival in patients treated with TKIs ( <a aria-describedby=\"bib20\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib20\"> 20 </a> , <a aria-describedby=\"bib21\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib21\"> 21 </a> ). High levels of serum albumin are also associated with reduced TNF\u03b1 and pro-inflammatory cytokine signaling, diminished gluconeogenesis, and increased activation of AKT to promote cell survival ( <a aria-describedby=\"bib22\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib22\"> 22 </a> ). This is consistent with the observation that the CB group had reduced levels of CPNE-1 (suggesting lower TNF\u03b1 signaling) and inflammatory proteins (ILF-2, ILF-3). There is mixed evidence about the role of PIGR in cancer, but some evidence suggests that PIGR promotes oncogenic AKT activity with downstream effects on GSK3B/\u03b2-catenin that are reversed by AKT inhibition ( <a aria-describedby=\"bib23\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib23\"> 23 </a> ). </p> <p> The 48 proteins that were downregulated in the CB group versus the NCB group cluster to three main nodes. The largest group includes 13 structural subunits of ribosomes. A related, strongly interconnected, node relates to regulation and processing of mRNA and DNA. The final node consists of 11 differentially expressed mitochondrial proteins. Taken as a whole, the nodes suggest strongly increased translational activity in the NCB group together with the associated energetic demands. GTP-binding protein SAR1a was the only one of the 53 differentially expressed proteins that overlapped with the proteins differentiating metastatic from primary tumors. </p> <p> Protein network analysis of the 48 downregulated proteins plus AKT1, using the String-DB, found 138 high-confidence interactions between proteins within this group ( <a class=\"usa-link\" href=\"#fig2\"> Fig. 2A </a> ). The observed protein\u2013protein interaction enrichment <em> P </em> -value of &lt;1.0e <sup> \u221216 </sup> provides strong evidence for a meaningful biological relationship between the proteins of interest in this dataset. Network analysis shows an enrichment of ribosomal proteins, mitochondrial proteins, and proteins involved in mRNA processing. </p> <figure class=\"fig xbox font-sm\" id=\"fig2\"> <h4 class=\"obj_head\"> Figure 2. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11320025_crc-24-0113_f2.jpg\" target=\"_blank\"> <img alt=\"Figure 2\" class=\"graphic zoom-in\" height=\"961\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f07/11320025/e31fd68f045b/crc-24-0113_f2.jpg\" width=\"777\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/fig2/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> Mapping of global proteomics results from CB vs. NCB groups to protein networks and pathways. <strong> A, </strong> Network analysis via String-DB plot of high-confidence protein\u2013protein interactions among proteins that are significantly different between CB and NCB group. Edges represent lines of evidence of protein\u2013protein interactions. Line colors indicate different evidence types: known interactions from curated databases (teal) or published experiments (pink), predicted interactions based on gene location (green), fusion (red), or co-occurrence (blue), or observed co-expression (black), protein homology (purple), or textmining relationships (lime). Major clusters are labeled according to shared features within the cluster. Nodes are overlaid from the Cytoscape visualization, with fold-change shown by color. Node size increases as the <em> P </em> -value decreases. <strong> B, </strong> Top 20 canonical pathways that are significantly differentially activated between clinical benefit (CB) and no clinical benefit (NCB) groups, based on assessment with Fisher\u2019s exact test in Qiagen IPA. The height of the bar corresponds to the confidence of an association, with a threshold of <em> P </em> &lt; 0.01. IPA\u2019s <em> Z </em> -score indicates the direction of regulation and extreme <em> z </em> -scores are depicted with increased color intensity. Orange bars represent increased activation in the NCB group whereas blue bars represent upregulated activity in the CB group. White bars indicate pathways with fewer than four mapped proteins or <em> z </em> -scores close to zero, indicating that the direction of regulation of individual pathway members does not strongly match a prespecified pattern. Gray bars indicate pathways for which no prediction can be made due to available evidence in the database. </p> </figcaption> </figure> </section> <section id=\"s3-3\"> <h3 class=\"pmc_sec_title\"> Proteins differentially expressed between the CB versus NCB groups map to translational control pathways </h3> <p> To better understand the pathways responsible for the group differences observed, QIAGEN\u2019s IPA software was used to systematically map the differentially expressed proteins, fold-changes, and <em> P </em> -values to canonical pathways and to statistically assess the observed patterns of regulation. Pathway enrichment analysis ( <a class=\"usa-link\" href=\"#fig2\"> Fig. 2B </a> ) identified a systematic enrichment of proteins in pathways associated with translational activity (e.g., EIF2 signaling, eIF4/p70S6K, mTOR pathway), inflammation (acute phase response signaling, LXR/RXR activation), cancer cell motility/invasion (actin cytoskeleton signaling), and altered glucose metabolism (gluconeogenesis, glycolysis). LXR/RXR was activated in the CB group. LXRs regulate glycolysis, lipid hemostasis, and possibly immune functions by enhancing the activity of GSK3\u03b2, which activates AKT and phosphorylates pathway proteins upstream ( <em> RICTOR </em> , <em> PTEN </em> ) and downstream ( <em> TSC </em> ) from AKT ( <a aria-describedby=\"bib24\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib24\"> 24 </a> ). Proteins belonging to translational control pathways directly downstream from AKT\u2014\u2013eIF4/p70S6K and mTOR signaling\u2014were enriched among the proteins of interest. Expression is upregulated for the associated proteins in the NCB group, though IPA could not statistically confirm the direction of regulation. </p> <p> The EIF2 signaling pathway is of particular interest in this context. eIF2\u03b1 (EIF2S1) is a master regulator of translation dysregulation in cancer. By modifying the efficiency of translation initiation, PERK-phosphorylated eIF2\u03b1 can selectively decrease or enhance translation, resulting in the uncoupling of mRNA abundance from protein expression for up to 90% of transcripts ( <a aria-describedby=\"bib25\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib25\"> 25 </a> ). Since eIF2\u03b1 works hand-in-hand with AKT to control cell fate decisions, sending compensatory prosurvival signals under conditions of cell stress, eIF2\u03b1 signaling has been previously identified as a possible mechanism of resistance to AKT inhibitors ( <a aria-describedby=\"bib25\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib25\"> 25 </a> \u2013 <a aria-describedby=\"bib27\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib27\"> 27 </a> ). Furthermore, the elevated expression of ribosomal and translational proteins observed in the NCB group could help sustain eIF2\u03b1 phosphorylation by limiting ER stress that could trigger the unfolded protein response and sensitize the cells to AKT inhibition ( <a aria-describedby=\"bib28\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib28\"> 28 </a> ). </p> <p> However, closer examination of the data shows that IPA defined its EIF2 pathway to include ribosomal proteins (RPL10A, RPL14, RPL18, RPLP0) that their EIF4 pathway does not. This led to statistical prioritization of EIF2 signaling in IPA but the authors could not find published evidence of a specific association of EIF2 signaling with these RPLs; in fact, the relationship appears to be mediated by EIF4. </p> </section> <section id=\"s3-4\"> <h3 class=\"pmc_sec_title\"> Targeted analysis in breast cancer cell lines reproduces the proteomic profile seen in patient samples </h3> <p> To further investigate the possible association of the identified proteins and pathways with capivasertib response, we implemented a specially developed multiplexed MRM-MS assay to directly quantify many of the proteins of interest ( <em> n </em> = 29) and related targets ( <em> n </em> = 16) with increased precision and reproducibility. The panel was applied to samples from HR <sup> + </sup> breast cancer cell lines with known activating PIK3CA or AKT1 alterations published in COSMIC (RRID:SCR_002260). Using a standard cytotoxicity assay, MCF-7 was confirmed to be capivasertib-sensitive (IC <sub> 50 </sub> &lt; 2 \u00b5mol/L), while HCC1428, ZR-75-30, and EFM-19 were found to be capivasertib-resistant (IC <sub> 50 </sub> &gt; 10 \u00b5mol/L; <a class=\"usa-link\" href=\"#fig3\"> Fig. 3A </a> ). Our CPTAC-validated assays were generally found to be fit-for-purpose in that 42 of the 54 proteins of interest were successfully quantified in most cell line samples. Hierarchical clustering separated sensitive (MCF-7, <em> n </em> = 4) from resistant (HCC1428, <em> n </em> = 3; ZR-75-30, <em> n </em> = 3; EFM-19, <em> n </em> = 3) cell lines on the basis of their expression of the proteins of interest ( <a class=\"usa-link\" href=\"#fig3\"> Fig. 3B </a> ). When an FDR-adjusted <em> t </em> test was applied, assuming unequal variance, three proteins (CBR1, HSP90AB1, HSPB1) were found to be significantly downregulated in the resistant cell lines and 14 were upregulated (FC &gt; 1.5; <em> P </em> &lt; 0.05). The proteomic profile observed in the capivasertib-resistant cell lines closely matched the profile observed in the tumors of patients in the NCB group. Of the 22 protein concentrations that best discriminated between sensitive versus resistant cell lines, 17 (77%) showed the same trend detected in the patient study ( <a class=\"usa-link\" href=\"#fig3\"> Fig. 3E </a> ; Supplementary Table S2). </p> <figure class=\"fig xbox font-sm\" id=\"fig3\"> <h4 class=\"obj_head\"> Figure 3. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11320025_crc-24-0113_f3.jpg\" target=\"_blank\"> <img alt=\"Figure 3\" class=\"graphic zoom-in\" height=\"1486\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f07/11320025/d9f85ae82a10/crc-24-0113_f3.jpg\" width=\"786\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/fig3/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> Statistical analysis of targeted protein quantitation in capivasertib-sensitive (green) and capivasertib-resistant (red) HR <sup> + </sup> <em> PIK3CA </em> -altered breast cancer cell lines. <strong> A, </strong> Schematic of experimental design for phase II of the study. <strong> B, </strong> Heatmap of protein concentrations quantified by MRM-MS with hierarchical clustering. <strong> C, </strong> Cell line sensitivity to capivasertib, expressed as IC <sub> 50 </sub> ( <strong> D </strong> ) Protein concentrations in capivasertib-sensitive vs. capivasertib-resistant cells ( <strong> E </strong> ) PCA (left) and PLS-DA plot (right). <strong> F, </strong> Top 22 features ranked by VIP scores, presented with the direction of change in capivasertib-resistant vs. capivasertib cell lines as compared to NCB vs. CB patient tumors. </p> </figcaption> </figure> <p> When quantified directly, expression of ATF4\u2014a protein whose increased expression directly transduces EIF2-driven translation\u2014is nearly identical between resistant and sensitive cell line samples. This result was further supported by the finding that combination treatment with capivasertib and an eIF2\u03b1 inhibitor (ISRIB, SelleckChem, S7400) did not yield synergistic effects in the capivasertib-resistant HCC-1428 cell line (Supplementary Fig. S4). While the relationships between the analyzed proteins are complex, the sum of the evidence is consistent with increased downstream mTORC1-driven translation in capivasertib-resistance ( <a class=\"usa-link\" href=\"#fig4\"> Fig. 4 </a> ). Increased upstream GSK\u03b2/mTORC2-activation might also be associated with capivasertib sensitivity. Given that EIF2 signaling is known to manage the balance between mTORC1 and mTORC2, a role for it cannot be ruled out. Prohibitins (PHB1/2) may be important determinants, as they are known to complex with RAF1 to activate the MEK-ERK pathway ( <a aria-describedby=\"bib29\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib29\"> 29 </a> ), which is a known mechanism of resistance to AKT inhibition ( <a aria-describedby=\"bib30\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib30\"> 30 </a> ), to increase AKT activity through positive feedback ( <a aria-describedby=\"bib31\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib31\"> 31 </a> ), and to support ribosome biogenesis ( <a aria-describedby=\"bib32\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib32\"> 32 </a> ). </p> <figure class=\"fig xbox font-sm\" id=\"fig4\"> <h4 class=\"obj_head\"> Figure 4. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11320025_crc-24-0113_f4.jpg\" target=\"_blank\"> <img alt=\"Figure 4\" class=\"graphic zoom-in\" height=\"667\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f07/11320025/77cf28ba9ff5/crc-24-0113_f4.jpg\" width=\"745\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/fig4/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> Schematic depicting proteins and pathways differently regulated in capivasertib-resistant cancers, as observed in patient tumors and breast cancer cell lines. Proteins with expression changes confirmed (FC &gt; 1.3; <em> P </em> &lt; 0.1) by MRM-MS data in cell lines are shown in red (increased), dark gray (no change), and green (decreased). Proteins with expression data from LFQ in patient tumor samples are shown in dark orange (increased) and dark blue (decreased). Light orange (activated) and light blue (inhibited) indicate proteins with predicted activity changes based on pathway analysis of the LFQ data. Proteins with no expression data are shown in light gray. (Figure Created with <a class=\"usa-link usa-link--external\" href=\"http://BioRender.com\" rel=\"noopener noreferrer\" target=\"_blank\"> BioRender.com </a> .) </p> </figcaption> </figure> </section> </section> <section id=\"s4\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"s4-anchor\"> </a> Discussion </h2> <p> <em> AKT </em> transcript overexpression is frequently observed, and is associated with tumor grade and aggressiveness, irrespective of AKT phosphorylation, in both <em> PIK3CA </em> -mutated and <em> PIK3CA </em> -wild-type tumors ( <a aria-describedby=\"bib33\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib33\"> 33 </a> , <a aria-describedby=\"bib34\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib34\"> 34 </a> ). We initially hypothesized that PI3K-altered tumors\u2019 AKT protein concentrations might better correlate with response to the AKT inhibitor capivasertib than genome-only based profiling, but this was not the case within our studied cohort. In addition, despite our expectation of high phospho-AKT concentrations reflecting PI3K pathway activation, few samples showed high phosphorylation levels. Experimental evidence suggests that maximal activation can occur when as little as 5% of the AKT pool is phosphorylated ( <a aria-describedby=\"bib35\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib35\"> 35 </a> ), so it is possible that available analytical approaches simply do not quantify such low-abundance modifications with the required precision. However, recent studies have also identified the potential for an uncoupling of AKT activity from <em> PIK3CA </em> mutations in some cancers ( <a aria-describedby=\"bib36\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib36\"> 36 </a> , <a aria-describedby=\"bib37\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib37\"> 37 </a> ). This includes the observation that protein levels of typical markers of pathway activity (e.g., pAKT, pS6, p4EBP1) may be unelevated or even markedly reduced in <em> PIK3CA </em> -mutated tumors ( <a aria-describedby=\"bib36\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib36\"> 36 </a> , <a aria-describedby=\"bib38\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib38\"> 38 </a> , <a aria-describedby=\"bib39\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib39\"> 39 </a> ). Understanding the reasons for this disconnect, is an ongoing effort in PI3K-targeted inhibitor development and requires investigation at the proteomic level. </p> <p> AKT1 and AKT2 protein levels did not differ significantly between the groups. Capivasertib also inhibits AKT3, which has been specifically associated with aggressive hard-to-treat disease and merits further attention in subsequent studies ( <a aria-describedby=\"bib40\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib40\"> 40 </a> ). Nonetheless, label-free quantitation data revealed a series of proteins that were differentially expressed between the CB and NCB groups. The profile observed in the CB group could be associated with greater upstream activation of AKT. Alternatively, higher levels of serum albumin and immune-related proteins could also reflect generally better prognosis, better immune infiltration, and greater perfusion of the tumors in the CB group that facilitates treatment. On the other hand, many of the proteins identified as higher in the NCB group have been previously linked to cancer progression, prognosis, and treatment response. For instance, specific subsets of ribosomal proteins have been identified as regulatory factors in various cancers ( <a aria-describedby=\"bib41\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib41\"> 41 </a> , <a aria-describedby=\"bib42\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib42\"> 42 </a> ). However, the clustering of differential proteins to a handful of interrelated functions, and functional linkages of the proteins to AKT activity, increase the confidence of the findings and support a specific association with response to capivasertib (vs. general prognostic value). </p> <p> Qiagen IPA analysis pointed to significant activation of EIF2 signaling, EIF4E/S6K and mTOR translational pathways in the NCB group and predicted that Rictor, a key component of mTORC2, may regulate the observed differences through higher activity in the CB group (Supplementary Table S3). As a means of further verifying this profile, we applied a newly validated proteomics panel to reproducibly quantify the proteins of interest from well-characterized cancer cell lines. Remarkably, the observed pattern of differences in protein expression was highly conserved between the patient tumor samples and the cell line model ( <a class=\"usa-link\" href=\"#fig4\"> Fig. 4 </a> ). The reproducibility of the profile associated with capivasertib resistance across two orthogonal proteomics approaches and two fully independent models lends significant credibility to the proteins\u2019 ability to detect capivasertib sensitivity. Moreover, the targeted assay panel provided key evidence against attributing the observed increase in translational activity specifically to EIF2 signaling, and instead highlighted the importance of downstream mTOR signaling. </p> <p> Given that no difference in AKT expression or phosphorylation were detected between the CB and NCB groups (both PI3K altered), this study suggests that variability in response to capivasertib monotherapy is likely due to differences in underlying mechanisms of resistance\u2014specifically the downstream mTORC1 activation and increased translation that is evident in the capivasertib-resistant groups. mTORC1-driven resistance to PI3K pathway inhibitors is now well-characterized ( <a aria-describedby=\"bib43\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib43\"> 43 </a> , <a aria-describedby=\"bib44\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib44\"> 44 </a> ). Previous research points to TSC1/2 or mTOR mutations as a mechanism for mTORC1-driven resistance; mTOR mutation has even been detected and effectively targeted in at least one patient ( <a aria-describedby=\"bib45\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib45\"> 45 </a> ). However, additional genetic mechanisms likely exist. Our results provide additional evidence for this pathway of resistance from the tumors of a small cohort of patients in a phase II clinical trial. Moreover, we present some of the first evidence that there is a significant proportion of patients in the genetically preselected intent-to-treat cohort whose tumors demonstrate increased mTORC1 activation years before drug exposure. These patients whose tumors show increased activation downstream from mTORC1 are predictably less likely to benefit from capivasertib monotherapy. The profile can be readily identified with a functional protein quantitation assay from tumor samples collected prior to capivasertib exposure. </p> </section> <section id=\"s5\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"s5-anchor\"> </a> Conclusion </h2> <p> The past almost two decades have seen the rapid emergence of precision medicine, which at first produced evidence that specific genomic variants found in subsets of patient tumors conferred remarkable clinical sensitivity to particular targeted treatments. When the limits of this approach became evident, studies like the WINTHER trial and others demonstrated the added value of transcriptomic data ( <a aria-describedby=\"bib46\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib46\"> 46 </a> ). Preclinical and clinical data have since demonstrated that protein levels can diverge from transcriptomic (mRNA) data and can assist in guiding choice of therapy ( <a aria-describedby=\"bib11\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib11\"> 11 </a> , <a aria-describedby=\"bib12\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib12\"> 12 </a> ). Our workflow in this study uniquely combined targeted and global proteomics technologies, making optimal use of volume-limited clinical samples and demonstrating the ability to obtain useful proteomic data from slide-mounted FFPE collected &gt;7 years prior. We further employed an innovative study model, employing preexisting cell lines to verify findings from clinical samples. </p> <p> Our data show the value of deeper molecular profiling at the protein level. We found that even in the context of an activating genetic mutation, downstream pathway activity varies sufficiently to alter treatment response. While many cancer cells exploit the PI3K pathway (even in the absence of detectable mutations), some are also primed to subvert AKT inhibition. That the mTORC1-driven profile can be readily observed at the protein level using the developed assay represents a significant opportunity for translation. The panel implemented here may facilitate detection of shifts in mTORC1 activity by downstream proteomic effects, even in the case of unknown or uncharacterized genetic changes, allowing for the correct stratification of patients with tumors whose mutations are not yet well characterize. Similar approaches may also prove valuable to characterize the proteomic profiles associated with sensitivity among tumors that are negative for <em> known </em> PI3K pathway alterations\u2014such as was seen in preclinical studies where capivasertib inhibited the growth of cancer cell lines without identifiable PI3K pathway alterations ( <a aria-describedby=\"bib47\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib47\"> 47 </a> ). Moreover, the example of EIF2 signaling activation\u2014where molecular changes are rapidly induced without concomitant genetic changes, resulting in uncoupling of the transcriptome and translatome\u2014is another reason to continue prioritizing a proteomics approach. </p> <p> Although the biological relationships observed in our data are compelling, the certainty of our findings is inherently limited by the limited number of samples analyzed and the heterogeneity of a heavily treated clinical population. CB may not accurately reflect treatment efficacy, especially in the absence of a comparator group (e.g., alternative or placebo treatment) to signal the natural history of disease in this small cohort. The imbalance between primary and metastatic origin for the patient samples also presents an important caveat, though this is partially addressed in our statistical analysis. The validated multiplexed proteomics assay will be a useful tool for future validation efforts, as precise quantitation with internal standards will enable reproducible measurement in larger cohorts and development of reference ranges. Long-term, large-scale randomized prospective studies are required to firmly establish the putative markers\u2019 utility for predicting treatment response in a specified setting. Additional mechanistic studies may also be of value, particularly for pinpointing additional co-targeting strategies (e.g., EIF4 inhibitors). </p> <p> Further studies will be needed to determine whether the observed profile can be extended to other cancer types, mutational contexts, or combination treatments. Capivasertib is currently being evaluated in phase III trials for activity as part of combination therapies in oncology settings such as prostate cancer, triple-negative breast cancer, and HR <sup> + </sup> breast cancer ( <a aria-describedby=\"bib9\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib9\"> 9 </a> , <a aria-describedby=\"bib48\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib48\"> 48 </a> , <a aria-describedby=\"bib49\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib49\"> 49 </a> ). Recent results of the CAPItello-291 phase III trial ( <a class=\"usa-link\" href=\"https://clinicaltrials.gov/ct2/show/NCT04305496\" rel=\"noopener noreferrer\" target=\"_blank\"> NCT04305496 </a> ) demonstrate that treatment with capivasertib + fulvestrant extends PFS in patients with HR <sup> + </sup> /HER2 <sup> \u2212 </sup> breast cancers with inadequate response to endocrine therapy. Evidence of treatment benefit was found in the overall population, including patients with and without identifiable AKT pathway alterations ( <a aria-describedby=\"bib50\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib50\"> 50 </a> ). As capivasertib moves into earlier stages of treatment and is prescribed to a broader group of patients, we will attempt to validate our findings in contemporaneous tissues, using an approach similar to our other biopsy-driven trials ( <a aria-describedby=\"bib51\" aria-expanded=\"false\" class=\"usa-link\" href=\"#bib51\"> 51 </a> ). </p> </section> <section id=\"sec18\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec18-anchor\"> </a> Supplementary Material </h2> <section class=\"sm xbox font-sm\" id=\"supplementary-material1\"> <div class=\"caption p\"> <span> Supplementary Methods S1 </span> <p> Supplemental Materials and Methods concerning patient samples, cell lines, tissue culture, iMALDI-MS, Nano-LC-Orbitrap-MS, LC-MRM-MS </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_methods_s1_suppsm1.pdf\"> crc-24-0113_supplementary_methods_s1_suppsm1.pdf </a> <sup> (780.8KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"supplementary-material2\"> <div class=\"caption p\"> <span> Supplementary Validation Data S1 </span> <p> Supplementary Validation Data demonstrating the performance of the iMALDI-MS assay </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_validation_data_s1_suppsd1.pdf\"> crc-24-0113_supplementary_validation_data_s1_suppsd1.pdf </a> <sup> (365.6KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"supplementary-material3\"> <div class=\"caption p\"> <span> Supplementary Validation Data S2 </span> <p> Quality Assessment of the Global Proteomics Data </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_validation_data_s2_suppsd2.pdf\"> crc-24-0113_supplementary_validation_data_s2_suppsd2.pdf </a> <sup> (121.9KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"supplementary-material4\"> <div class=\"caption p\"> <span> Supplementary Figure S1 </span> <p> Individual protein concentrations measured by iMALDI-MS for each sample, comparison of measured PTEN concentration to IHC H-score </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_figure_s1_suppsf1.pdf\"> crc-24-0113_supplementary_figure_s1_suppsf1.pdf </a> <sup> (387.1KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"supplementary-material5\"> <div class=\"caption p\"> <span> Supplementary Figure S2 </span> <p> Individual protein concentrations measured by iMALDI-MS for PTEN vs. IHC H-score </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_figure_s2_suppsf2.pdf\"> crc-24-0113_supplementary_figure_s2_suppsf2.pdf </a> <sup> (372KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"supplementary-material6\"> <div class=\"caption p\"> <span> Supplementary Figure S3 </span> <p> Comparison of iMALDI and Global Proteomics results for primary vs metastatic samples </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_figure_s3_suppsf3.pdf\"> crc-24-0113_supplementary_figure_s3_suppsf3.pdf </a> <sup> (492.6KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"supplementary-material7\"> <div class=\"caption p\"> <span> Supplementary Figure S4 </span> <p> Combination treatment of cell lines with capivasertib and an eIF2\u03b1 inhibitor </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_figure_s4_suppsf4.pdf\"> crc-24-0113_supplementary_figure_s4_suppsf4.pdf </a> <sup> (1.2MB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"supplementary-material8\"> <div class=\"caption p\"> <span> Supplementary Table S1 </span> <p> Detailed results of the label-free quantitation </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_table_s1_suppst1.pdf\"> crc-24-0113_supplementary_table_s1_suppst1.pdf </a> <sup> (110.9KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"supplementary-material9\"> <div class=\"caption p\"> <span> Supplementary Table S2 </span> <p> Proteins expression differences between capivasertib-resistant vs. capivasertib-sensitive cells quantified by validated MRM-MS assays as compared to the profile observed in patient samples </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_table_s2_suppst2.pdf\"> crc-24-0113_supplementary_table_s2_suppst2.pdf </a> <sup> (122.2KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"supplementary-material10\"> <div class=\"caption p\"> <span> Supplementary Table S3 </span> <p> Detailed results of pathway mapping by Qiagen IPA </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_table_s3_suppst3.pdf\"> crc-24-0113_supplementary_table_s3_suppst3.pdf </a> <sup> (109.5KB, pdf) </sup> </div> </div> </section> </section> <section class=\"ack\" id=\"ack1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"ack1-anchor\"> </a> Acknowledgments </h2> <p> This research was funded by Genome Canada under the Genomics Technology Platform program (#264PRO) and the Genomics Applied Partnership Program (#183AKT and PD-L1), with co-funding from Genome British Columbia (#264PRO, #183AKT). Graduate research funding for C.A. Sobsey was provided by the Fonds De Recherche Du Qu\u00e9bec - Sant\u00e9 (FRQS #254160) and the Faculty of Medicine, McGill University (Max Binz Fellowship, Charles James Patton, M.D., and Elizabeth Ross Patton Memorial Prize). We would like to thank AstraZeneca for their partnership in this project. Capivasertib was discovered by AstraZeneca, subsequent to a collaboration with Astex Therapeutics (and its collaboration with the Institute of Cancer Research and Cancer Research Technology Limited). Special thanks to Dr. Gaia Schiavon for her work in establishing this partnership and bringing the project to fruition. Thank you to the laboratory of Dr. Mark Basik at the Segal Cancer Centre for providing samples of breast cancer cell lines for this project. Special thanks also to Drs. Adriana Aguilar-Mahecha and Tahar Aboulkassim for their support for the cell line experiments. C.H. Borchers is grateful for support from the Segal McGill Chair in Molecular Oncology at McGill University, and for support from the Warren Y. Soper Charitable Trust for the Warren Y. Soper Clinical Proteomics Centre at the Jewish General Hospital (Montr\u00e9al, Quebec, Canada). C.H. Borchers is also grateful for support from the Terry Fox Research Institute and the Alvin Segal Family Foundation for the Segal Cancer Proteomics Centre at the Jewish General Hospital (Montr\u00e9al, Quebec, Canada). The authors are also grateful for support from the Quebec Cancer Consortium. We offer special thanks to patients who participate in clinical trials, without whom this research would not have been possible. This work was done under the auspices of a Memorandum of Understanding between McGill and the U.S. National Cancer Institute\u2019s International Cancer Proteogenome Consortium (ICPC). ICPC encourages international cooperation among institutions and nations in proteogenomic cancer research in which proteogenomic datasets are made available to the public. This work was also done in collaboration with the U.S. National Cancer Institute\u2019s Clinical Proteomic Tumor Analysis Consortium (CPTAC). </p> </section> <section class=\"app\" id=\"app1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"app1-anchor\"> </a> Appendix Gene and protein names. </h2> <section class=\"tw xbox font-sm\" id=\"audtbl1\"> <div class=\"tbl-box p\" tabindex=\"0\"> <table class=\"content\" frame=\"hsides\" rules=\"groups\"> <thead> <tr> <th align=\"left\" colspan=\"1\" rowspan=\"1\"> Gene </th> <th align=\"left\" colspan=\"1\" rowspan=\"1\"> Abbreviation </th> <th align=\"left\" colspan=\"1\" rowspan=\"1\"> Uniprot </th> <th align=\"left\" colspan=\"1\" rowspan=\"1\"> Protein name </th> </tr> </thead> <tbody> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> EIF4EBP1 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> (p) 4E-BP1 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q13541\" rel=\"noopener noreferrer\" target=\"_blank\"> Q13541 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Eukaryotic translation initiation factor 4E-binding protein 1 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> AHCY </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> AdoHcyase </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P23526\" rel=\"noopener noreferrer\" target=\"_blank\"> P23526 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Adenosylhomocysteinase </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> AKT1 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> (p)AKT1 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P31749\" rel=\"noopener noreferrer\" target=\"_blank\"> P31749 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> RAC-alpha serine/threonine-protein kinase </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> AKT2 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> (p)AKT2 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P31751\" rel=\"noopener noreferrer\" target=\"_blank\"> P31751 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> RAC-beta serine/threonine-protein kinase </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> ALB </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Albumin </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P02768\" rel=\"noopener noreferrer\" target=\"_blank\"> P02768 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Albumin </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> AMPK </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> AMPK \u03b1-2 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P54646\" rel=\"noopener noreferrer\" target=\"_blank\"> P54646 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 5\u2032-AMP-activated protein kinase catalytic subunit alpha-2 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> APRT </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> APRT </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P07741\" rel=\"noopener noreferrer\" target=\"_blank\"> P07741 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Adenine phosphoribosyltransferase </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> ARHGAP1 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> p50-RhoGAP </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q07960\" rel=\"noopener noreferrer\" target=\"_blank\"> Q07960 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Rho GTPase-activating protein 1 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> ARPC4 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> ARPC4 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P59998\" rel=\"noopener noreferrer\" target=\"_blank\"> P59998 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Actin-related protein 2/3 complex subunit 4 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> ATF4 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> ATF4 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P18848\" rel=\"noopener noreferrer\" target=\"_blank\"> P18848 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Cyclic AMP-dependent transcription factor ATF-4 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> CCT3 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> TCP-1-gamma </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P49368\" rel=\"noopener noreferrer\" target=\"_blank\"> P49368 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> T-complex protein 1 subunit gamma </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> CCT8 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> TCP-1-theta </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P50990\" rel=\"noopener noreferrer\" target=\"_blank\"> P50990 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> T-complex protein 1 subunit theta </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> CPNE1 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Copine I </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q99829\" rel=\"noopener noreferrer\" target=\"_blank\"> Q99829 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Copine-1 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> DCXR </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> XR </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q7Z4W1\" rel=\"noopener noreferrer\" target=\"_blank\"> Q7Z4W1 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> L-xylulose reductase </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> DECR1 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> DECR </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q16698\" rel=\"noopener noreferrer\" target=\"_blank\"> Q16698 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing], mitochondrial </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> EIF2A </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> eIF-2A </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q9BY44\" rel=\"noopener noreferrer\" target=\"_blank\"> Q9BY44 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Eukaryotic translation initiation factor 2A </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> EIF2AK3 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> PEK, PERK </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q9NZJ5\" rel=\"noopener noreferrer\" target=\"_blank\"> Q9NZJ5 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Eukaryotic translation initiation factor 2-alpha kinase 3 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> EIF2S1 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> eIF2\u03b1 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P05198\" rel=\"noopener noreferrer\" target=\"_blank\"> P05198 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Eukaryotic translation initiation factor 2 subunit 1 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> EIF3E </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> eIF3e </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P60228\" rel=\"noopener noreferrer\" target=\"_blank\"> P60228 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Eukaryotic translation initiation factor 3 subunit E </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> EIF4A1 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> eIF4A-I </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P60842\" rel=\"noopener noreferrer\" target=\"_blank\"> P60842 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Eukaryotic initiation factor 4A-I </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> EIF4E </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> eIF4E </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P06730\" rel=\"noopener noreferrer\" target=\"_blank\"> P06730 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Eukaryotic translation initiation factor 4E </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> EIF5 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> eIF-5 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P55010\" rel=\"noopener noreferrer\" target=\"_blank\"> P55010 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Eukaryotic translation initiation factor 5 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> ETFB </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Beta-ETF </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P38117\" rel=\"noopener noreferrer\" target=\"_blank\"> P38117 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Electron transfer flavoprotein subunit beta </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> GSK3B </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> GSK-3Beta </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P49841\" rel=\"noopener noreferrer\" target=\"_blank\"> P49841 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Glycogen synthase kinase-3 beta </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> HADHB </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> TP-Beta </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P55084\" rel=\"noopener noreferrer\" target=\"_blank\"> P55084 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Trifunctional enzyme subunit beta, mitochondrial </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> HK1 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> HK I </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P19367\" rel=\"noopener noreferrer\" target=\"_blank\"> P19367 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Hexokinase-1 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> HNRNP-F </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> hnRNP F </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P52597\" rel=\"noopener noreferrer\" target=\"_blank\"> P52597 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Heterogeneous nuclear ribonucleoprotein F </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> HNRNP-L </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> hnRNP L </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P14866\" rel=\"noopener noreferrer\" target=\"_blank\"> P14866 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Heterogeneous nuclear ribonucleoprotein L </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> IGKC </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> IGKC </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P01834\" rel=\"noopener noreferrer\" target=\"_blank\"> P01834 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Immunoglobulin kappa constant </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> IGKV4 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> IGKV4-1 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P06312\" rel=\"noopener noreferrer\" target=\"_blank\"> P06312 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Immunoglobulin kappa variable 4\u20131 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> ILF2 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> ILF2 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q12905\" rel=\"noopener noreferrer\" target=\"_blank\"> Q12905 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Interleukin enhancer-binding factor 2 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> ILF3 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> ILF3 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q12906\" rel=\"noopener noreferrer\" target=\"_blank\"> Q12906 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Interleukin enhancer-binding factor 3 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> KRAS </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> K-Ras 2 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P01116\" rel=\"noopener noreferrer\" target=\"_blank\"> P01116 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> GTPase KRas </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> MAPK1 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> MAP kinase 1, ERK2 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P28482\" rel=\"noopener noreferrer\" target=\"_blank\"> P28482 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Mitogen-activated protein kinase 1 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> MDH2 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> MDH2 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P40926\" rel=\"noopener noreferrer\" target=\"_blank\"> P40926 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Malate dehydrogenase, mitochondrial </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> MTOR </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> mTOR </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P42345\" rel=\"noopener noreferrer\" target=\"_blank\"> P42345 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Serine/threonine-protein kinase mTOR </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> MYC </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> c-Myc </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P01106\" rel=\"noopener noreferrer\" target=\"_blank\"> P01106 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Myc proto-oncogene protein </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> PCBP1 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> hnRNP E1 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q15365\" rel=\"noopener noreferrer\" target=\"_blank\"> Q15365 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Poly (rC)-binding protein 1 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> PCBP2 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> hnRNP E2 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q15366\" rel=\"noopener noreferrer\" target=\"_blank\"> Q15366 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Poly (rC)-binding protein 2 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> PDIA6 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> ERp5 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q15084\" rel=\"noopener noreferrer\" target=\"_blank\"> Q15084 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Protein disulfide-isomerase A6/Endoplasmic reticulum protein 5 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> PHB1 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> PHB1 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P35232\" rel=\"noopener noreferrer\" target=\"_blank\"> P35232 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Prohibitin 1 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> PHB2 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> PHB2 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q99623\" rel=\"noopener noreferrer\" target=\"_blank\"> Q99623 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Prohibitin-2 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> PIGR </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> PIgR </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P01833\" rel=\"noopener noreferrer\" target=\"_blank\"> P01833 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Polymeric immunoglobulin receptor </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> PIK3CA </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> PIK3CA, p110\u03b1 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P42336\" rel=\"noopener noreferrer\" target=\"_blank\"> P42336 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> PIK3CB </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> PIK3C-Beta </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P42338\" rel=\"noopener noreferrer\" target=\"_blank\"> P42338 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> PSMA6 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> PSMA6 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P60900\" rel=\"noopener noreferrer\" target=\"_blank\"> P60900 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Proteasome subunit alpha type-6 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> PTEN </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> PTEN </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P60484\" rel=\"noopener noreferrer\" target=\"_blank\"> P60484 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> RICTOR </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Rictor </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q6R327\" rel=\"noopener noreferrer\" target=\"_blank\"> Q6R327 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Rapamycin-insensitive companion of mTOR </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> RPS6KB1 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> (p)S6K1 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P23443\" rel=\"noopener noreferrer\" target=\"_blank\"> P23443 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Ribosomal protein S6 kinase beta-1 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> SDHA </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> SDHA </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P31040\" rel=\"noopener noreferrer\" target=\"_blank\"> P31040 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> SEPTIN2 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Septin-2 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q15019\" rel=\"noopener noreferrer\" target=\"_blank\"> Q15019 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Septin-2 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> SLC25A3 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> PTP </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q00325\" rel=\"noopener noreferrer\" target=\"_blank\"> Q00325 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Phosphate carrier protein, mitochondrial </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> TNF </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> TNF\u03b1 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P01375\" rel=\"noopener noreferrer\" target=\"_blank\"> P01375 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Tumor necrosis factor alpha </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> TSC1 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Hamartin </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q92574\" rel=\"noopener noreferrer\" target=\"_blank\"> Q92574 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Tuberous sclerosis 1 protein </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> TSC2 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Tuberin </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P49815\" rel=\"noopener noreferrer\" target=\"_blank\"> P49815 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Tuberous sclerosis 2 protein </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> TSTA3 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> TSTA3 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/Q13630\" rel=\"noopener noreferrer\" target=\"_blank\"> Q13630 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> GDP-L-fucose synthase </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> TUFM </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> EF-Tu, P43 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P49411\" rel=\"noopener noreferrer\" target=\"_blank\"> P49411 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Elongation factor Tu, mitochondrial </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <em> XRCC5 </em> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> XRCC5 </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/P13010\" rel=\"noopener noreferrer\" target=\"_blank\"> P13010 </a> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> X-ray repair cross-complementing protein 5 </td> </tr> </tbody> </table> </div> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"table/audtbl1/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> </section> </section> <section class=\"fn-group\" id=\"fn-group1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"fn-group1-anchor\"> </a> Footnotes </h2> <div class=\"fn-group p font-secondary-light font-sm\"> <div class=\"fn p\" id=\"fn3\"> <p> <strong> Note: </strong> Supplementary data for this article are available at Cancer Research Communications Online ( <a class=\"usa-link usa-link--external\" href=\"https://aacrjournals.org/cancerrescommun/\" rel=\"noopener noreferrer\" target=\"_blank\"> https://aacrjournals.org/cancerrescommun/ </a> ). </p> </div> </div> </section> <section id=\"s6\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"s6-anchor\"> </a> Authors\u2019 Disclosures </h2> <p> R.P. Zahedi reports personal fees from MRM Proteomics Inc. outside the submitted work. E.C. de Bruin reports AstraZeneca employee and holds AstraZeneca shares. C.H. Borchers reports grants from Genome Canada and Genome Quebec, and other support from AstraZeneca during the conduct of the study; C.H. Borchers is the C.S.O. of MRM Proteomics, Inc. and the V.P. of Proteomics at Molecular You outside the submitted work. No other disclosures were reported. </p> </section> <section id=\"s7\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"s7-anchor\"> </a> Authors\u2019 Contributions </h2> <p> <strong> C.A. Sobsey </strong> : Conceptualization, data curation, formal analysis, funding acquisition, validation, investigation, visualization, methodology, writing-original draft, project administration, writing-review and editing. <strong> B.C. Froehlich </strong> : Software, investigation, visualization. <strong> G. Mitsa </strong> : Investigation, methodology. <strong> S. Ibrahim </strong> : Investigation, methodology. <strong> R. Popp </strong> : Investigation, methodology. <strong> R.P. Zahedi </strong> : Formal analysis, supervision, methodology, project administration, writing-review and editing. <strong> E.C. de Bruin </strong> : Resources, data curation, methodology, writing-review and editing. <strong> C.H. Borchers </strong> : Conceptualization, resources, data curation, formal analysis, supervision, funding acquisition, methodology, project administration, writing-review and editing. <strong> G. Batist </strong> : Conceptualization, resources, data curation, supervision, funding acquisition, methodology, project administration, writing-review and editing. </p> </section> <section class=\"ref-list\" id=\"ref-list1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"ref-list1-anchor\"> </a> References </h2> <section id=\"ref-list1_sec2\"> <ul class=\"ref-list font-sm\"> <li id=\"bib1\"> <span class=\"label\"> 1. </span> <cite> Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R. Landscape of phosphatidylinositol-3-kinase pathway alterations across 19 784 diverse solid tumors. JAMA Oncol 2016;2:1565\u201373. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1001/jamaoncol.2016.0891\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/27388585/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol&amp;title=Landscape%20of%20phosphatidylinositol-3-kinase%20pathway%20alterations%20across%2019%20784%20diverse%20solid%20tumors&amp;volume=2&amp;publication_year=2016&amp;pages=1565-73&amp;pmid=27388585&amp;doi=10.1001/jamaoncol.2016.0891&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib2\"> <span class=\"label\"> 2. </span> <cite> Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550\u201362. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nrc2664\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/19629070/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Cancer&amp;title=Targeting%20PI3K%20signalling%20in%20cancer:%20opportunities,%20challenges%20and%20limitations&amp;volume=9&amp;publication_year=2009&amp;pages=550-62&amp;pmid=19629070&amp;doi=10.1038/nrc2664&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib3\"> <span class=\"label\"> 3. </span> <cite> De Luca A, Maiello MR, D\u2019Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012;16(Suppl 2):S17\u201327. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1517/14728222.2011.639361\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/22443084/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Expert%20Opin%20Ther%20Targets&amp;title=The%20RAS/RAF/MEK/ERK%20and%20the%20PI3K/AKT%20signalling%20pathways:%20role%20in%20cancer%20pathogenesis%20and%20implications%20for%20therapeutic%20approaches&amp;volume=16&amp;issue=Suppl%202&amp;publication_year=2012&amp;pages=S17-27&amp;pmid=22443084&amp;doi=10.1517/14728222.2011.639361&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib4\"> <span class=\"label\"> 4. </span> <cite> Nitulescu GM, Margina D, Juzenas P, Peng Q, Olaru OT, Saloustros E, et al. Akt inhibitors in cancer treatment: the long journey from drug discovery to clinical use (Review). Int J Oncol 2016;48:869\u201385. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.3892/ijo.2015.3306\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4750533/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26698230/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Int%20J%20Oncol&amp;title=Akt%20inhibitors%20in%20cancer%20treatment:%20the%20long%20journey%20from%20drug%20discovery%20to%20clinical%20use%20(Review)&amp;volume=48&amp;publication_year=2016&amp;pages=869-85&amp;pmid=26698230&amp;doi=10.3892/ijo.2015.3306&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib5\"> <span class=\"label\"> 5. </span> <cite> Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in hormone receptor\u2013positive advanced breast cancer. N Engl J Med 2023;388:2058\u201370. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1056/NEJMoa2214131\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC11335038/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/37256976/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Capivasertib%20in%20hormone%20receptor%E2%80%93positive%20advanced%20breast%20cancer&amp;volume=388&amp;publication_year=2023&amp;pages=2058-70&amp;pmid=37256976&amp;doi=10.1056/NEJMoa2214131&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib6\"> <span class=\"label\"> 6. </span> <cite> Banerji U, Dean EJ, P\u00e9rez-Fidalgo JA, Batist G, Bedard PL, You B, et al. A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in <em> PIK3CA </em> -mutated breast and gynecologic cancers. Clin Cancer Res 2018;24:2050\u20139. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1158/1078-0432.CCR-17-2260\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/29066505/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=A%20phase%20I%20open-label%20study%20to%20identify%20a%20dosing%20regimen%20of%20the%20pan-AKT%20inhibitor%20AZD5363%20for%20evaluation%20in%20solid%20tumors%20and%20in%20PIK3CA-mutated%20breast%20and%20gynecologic%20cancers&amp;volume=24&amp;publication_year=2018&amp;pages=2050-9&amp;pmid=29066505&amp;doi=10.1158/1078-0432.CCR-17-2260&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib7\"> <span class=\"label\"> 7. </span> <cite> Smyth LM, Tamura K, Oliveira M, Ciruelos EM, Mayer IA, Sablin MP, et al. Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with <em> AKT1 </em> <sup> E17K </sup> -mutant, ER-positive metastatic breast cancer. Clin Cancer Res 2020;26:3947\u201357. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1158/1078-0432.CCR-19-3953\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7415507/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/32312891/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Capivasertib,%20an%20AKT%20kinase%20inhibitor,%20as%20monotherapy%20or%20in%20combination%20with%20fulvestrant%20in%20patients%20with%20AKT1E17K-mutant,%20ER-positive%20metastatic%20breast%20cancer&amp;volume=26&amp;publication_year=2020&amp;pages=3947-57&amp;pmid=32312891&amp;doi=10.1158/1078-0432.CCR-19-3953&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib8\"> <span class=\"label\"> 8. </span> <cite> Kalinsky K, Hong F, McCourt CK, Sachdev JC, Mitchell EP, Zwiebel JA, et al. Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial. JAMA Oncol 2021;7:271\u20138. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1001/jamaoncol.2020.6741\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7774047/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/33377972/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol&amp;title=Effect%20of%20capivasertib%20in%20patients%20with%20an%20AKT1%20E17K-mutated%20tumor:%20NCI-MATCH%20subprotocol%20EAY131-Y%20nonrandomized%20trial&amp;volume=7&amp;publication_year=2021&amp;pages=271-8&amp;pmid=33377972&amp;doi=10.1001/jamaoncol.2020.6741&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib9\"> <span class=\"label\"> 9. </span> <cite> Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2020;21:345\u201357. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/S1470-2045(19)30817-4\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7052734/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/32035020/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Fulvestrant%20plus%20capivasertib%20versus%20placebo%20after%20relapse%20or%20progression%20on%20an%20aromatase%20inhibitor%20in%20metastatic,%20oestrogen%20receptor-positive%20breast%20cancer%20(FAKTION):%20a%20multicentre,%20randomised,%20controlled,%20phase%202%20trial&amp;volume=21&amp;publication_year=2020&amp;pages=345-57&amp;pmid=32035020&amp;doi=10.1016/S1470-2045(19)30817-4&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib10\"> <span class=\"label\"> 10. </span> <cite> Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol 2022;23:851\u201364. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/S1470-2045(22)00284-4\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC9630162/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/35671774/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Fulvestrant%20plus%20capivasertib%20versus%20placebo%20after%20relapse%20or%20progression%20on%20an%20aromatase%20inhibitor%20in%20metastatic,%20oestrogen%20receptor-positive,%20HER2-negative%20breast%20cancer%20(FAKTION):%20overall%20survival,%20updated%20progression-free%20survival,%20and%20expanded%20biomarker%20analysis%20from%20a%20randomised,%20phase%202%20trial&amp;volume=23&amp;publication_year=2022&amp;pages=851-64&amp;pmid=35671774&amp;doi=10.1016/S1470-2045(22)00284-4&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib11\"> <span class=\"label\"> 11. </span> <cite> Li L, Wei Y, To C, Zhu CQ, Tong J, Pham NA, et al. Integrated omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. Nat Commun 2014;5:5469. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/ncomms6469\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/25429762/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Integrated%20omic%20analysis%20of%20lung%20cancer%20reveals%20metabolism%20proteome%20signatures%20with%20prognostic%20impact&amp;volume=5&amp;publication_year=2014&amp;pages=5469&amp;pmid=25429762&amp;doi=10.1038/ncomms6469&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib12\"> <span class=\"label\"> 12. </span> <cite> Roumeliotis TI, Williams SP, Goncalves E, Alsinet C, Del Castillo Velasco-Herrera M, Aben N, et al. Genomic determinants of protein abundance variation in colorectal cancer cells. Cell Rep 2017;20:2201\u201314. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.celrep.2017.08.010\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5583477/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/28854368/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cell%20Rep&amp;title=Genomic%20determinants%20of%20protein%20abundance%20variation%20in%20colorectal%20cancer%20cells&amp;volume=20&amp;publication_year=2017&amp;pages=2201-14&amp;pmid=28854368&amp;doi=10.1016/j.celrep.2017.08.010&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib13\"> <span class=\"label\"> 13. </span> <cite> Popp R, Li H, LeBlanc A, Mohammed Y, Aguilar-Mahecha A, Chambers AG, et al. Immuno-matrix-assisted laser desorption/ionization assays for quantifying AKT1 and AKT2 in breast and colorectal cancer cell lines and tumors. Anal Chem 2017;89:10592\u2013600. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1021/acs.analchem.7b02934\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/28853539/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Anal%20Chem&amp;title=Immuno-matrix-assisted%20laser%20desorption/ionization%20assays%20for%20quantifying%20AKT1%20and%20AKT2%20in%20breast%20and%20colorectal%20cancer%20cell%20lines%20and%20tumors&amp;volume=89&amp;publication_year=2017&amp;pages=10592-600&amp;pmid=28853539&amp;doi=10.1021/acs.analchem.7b02934&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib14\"> <span class=\"label\"> 14. </span> <cite> Domanski D, Murphy LC, Borchers CH. Assay development for the determination of phosphorylation stoichiometry using multiple reaction monitoring methods with and without phosphatase treatment: application to breast cancer signaling pathways. Anal Chem 2010;82:5610\u201320. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1021/ac1005553\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC2909760/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/20524616/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Anal%20Chem&amp;title=Assay%20development%20for%20the%20determination%20of%20phosphorylation%20stoichiometry%20using%20multiple%20reaction%20monitoring%20methods%20with%20and%20without%20phosphatase%20treatment:%20application%20to%20breast%20cancer%20signaling%20pathways&amp;volume=82&amp;publication_year=2010&amp;pages=5610-20&amp;pmid=20524616&amp;doi=10.1021/ac1005553&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib15\"> <span class=\"label\"> 15. </span> <cite> Froehlich BC, Popp R, Sobsey CA, Ibrahim S, LeBlanc A, Mohammed Y, et al. A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110\u03b1 in cell lines and tumor tissues. Analyst 2021;146:6566\u201375. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1039/d1an00165e\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/34585690/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Analyst&amp;title=A%20multiplexed,%20automated%20immuno-matrix%20assisted%20laser%20desorption/ionization%20mass%20spectrometry%20assay%20for%20simultaneous%20and%20precise%20quantitation%20of%20PTEN%20and%20p110%CE%B1%20in%20cell%20lines%20and%20tumor%20tissues&amp;volume=146&amp;publication_year=2021&amp;pages=6566-75&amp;pmid=34585690&amp;doi=10.1039/d1an00165e&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib16\"> <span class=\"label\"> 16. </span> <cite> Whiteaker JR, Halusa GN, Hoofnagle AN, Sharma V, MacLean B, Yan P, et al. CPTAC assay portal: a repository of targeted proteomic assays. Nat Methods 2014;11:703\u20134. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nmeth.3002\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4113142/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/24972168/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Methods&amp;title=CPTAC%20assay%20portal:%20a%20repository%20of%20targeted%20proteomic%20assays&amp;volume=11&amp;publication_year=2014&amp;pages=703-4&amp;pmid=24972168&amp;doi=10.1038/nmeth.3002&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib17\"> <span class=\"label\"> 17. </span> <cite> Pang Z, Chong J, Zhou G, de Lima Morais DA, Chang L, Barrette M, et al. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res 2021;49:W388\u201396. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/nar/gkab382\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC8265181/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/34019663/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nucleic%20Acids%20Res&amp;title=MetaboAnalyst%205.0:%20narrowing%20the%20gap%20between%20raw%20spectra%20and%20functional%20insights&amp;volume=49&amp;publication_year=2021&amp;pages=W388-96&amp;pmid=34019663&amp;doi=10.1093/nar/gkab382&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib18\"> <span class=\"label\"> 18. </span> <cite> Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein\u2013protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res 2021;49:D605\u201312. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/nar/gkaa1074\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7779004/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/33237311/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nucleic%20Acids%20Res&amp;title=The%20STRING%20database%20in%202021:%20customizable%20protein%E2%80%93protein%20networks,%20and%20functional%20characterization%20of%20user-uploaded%20gene/measurement%20sets&amp;volume=49&amp;publication_year=2021&amp;pages=D605-12&amp;pmid=33237311&amp;doi=10.1093/nar/gkaa1074&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib19\"> <span class=\"label\"> 19. </span> <cite> Doncheva NT, Morris JH, Gorodkin J, Jensen LJ. Cytoscape StringApp: network analysis and visualization of proteomics data. J Proteome Res 2019;18:623\u201332. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1021/acs.jproteome.8b00702\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC6800166/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/30450911/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Proteome%20Res&amp;title=Cytoscape%20StringApp:%20network%20analysis%20and%20visualization%20of%20proteomics%20data&amp;volume=18&amp;publication_year=2019&amp;pages=623-32&amp;pmid=30450911&amp;doi=10.1021/acs.jproteome.8b00702&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib20\"> <span class=\"label\"> 20. </span> <cite> Fiala O, Pesek M, Finek J, Racek J, Minarik M, Benesova L, et al. Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib. Neoplasma 2016;63:471\u20136. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.4149/318_151001N512\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26952513/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Neoplasma&amp;title=Serum%20albumin%20is%20a%20strong%20predictor%20of%20survival%20in%20patients%20with%20advanced-stage%20non-small%20cell%20lung%20cancer%20treated%20with%20erlotinib&amp;volume=63&amp;publication_year=2016&amp;pages=471-6&amp;pmid=26952513&amp;doi=10.4149/318_151001N512&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib21\"> <span class=\"label\"> 21. </span> <cite> Dalmiglio C, Brilli L, Campanile M, Ciuoli C, Cartocci A, Castagna MG. CONUT score: a new tool for predicting prognosis in patients with advanced thyroid cancer treated with TKI. Cancers (Basel) 2022;14:724. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.3390/cancers14030724\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC8833681/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/35158991/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancers%20(Basel)&amp;title=CONUT%20score:%20a%20new%20tool%20for%20predicting%20prognosis%20in%20patients%20with%20advanced%20thyroid%20cancer%20treated%20with%20TKI&amp;volume=14&amp;publication_year=2022&amp;pages=724&amp;pmid=35158991&amp;doi=10.3390/cancers14030724&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib22\"> <span class=\"label\"> 22. </span> <cite> Jones DT, Ganeshaguru K, Anderson RJ, Jackson TR, Bruckdorfer KR, Low SY, et al. Albumin activates the AKT signaling pathway and protects B-chronic lymphocytic leukemia cells from chlorambucil- and radiation-induced apoptosis. Blood 2003;101:3174\u201380. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1182/blood-2002-07-2143\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/12480711/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Albumin%20activates%20the%20AKT%20signaling%20pathway%20and%20protects%20B-chronic%20lymphocytic%20leukemia%20cells%20from%20chlorambucil-%20and%20radiation-induced%20apoptosis&amp;volume=101&amp;publication_year=2003&amp;pages=3174-80&amp;pmid=12480711&amp;doi=10.1182/blood-2002-07-2143&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib23\"> <span class=\"label\"> 23. </span> <cite> Tey SK, Wong SWK, Chan JYT, Mao X, Ng TH, Yeung CLS, et al. Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma. J Hepatol 2022;76:883\u201395. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.jhep.2021.12.005\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/34922977/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Hepatol&amp;title=Patient%20pIgR-enriched%20extracellular%20vesicles%20drive%20cancer%20stemness,%20tumorigenesis%20and%20metastasis%20in%20hepatocellular%20carcinoma&amp;volume=76&amp;publication_year=2022&amp;pages=883-95&amp;pmid=34922977&amp;doi=10.1016/j.jhep.2021.12.005&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib24\"> <span class=\"label\"> 24. </span> <cite> Dianat-Moghadam H, Khalili M, Keshavarz M, Azizi M, Hamishehkar H, Rahbarghazi R, et al. Modulation of LXR signaling altered the dynamic activity of human colon adenocarcinoma cancer stem cells <em> in vitro </em> . Cancer Cell Int 2021;21:100. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1186/s12935-021-01803-4\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7877018/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/33568147/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell%20Int&amp;title=Modulation%20of%20LXR%20signaling%20altered%20the%20dynamic%20activity%20of%20human%20colon%20adenocarcinoma%20cancer%20stem%20cells%20in%20vitro&amp;volume=21&amp;publication_year=2021&amp;pages=100&amp;pmid=33568147&amp;doi=10.1186/s12935-021-01803-4&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib25\"> <span class=\"label\"> 25. </span> <cite> Holcik M. Could the eIF2alpha-independent translation be the achilles heel of cancer? Front Oncol 2015;5:264. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.3389/fonc.2015.00264\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4659918/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26636041/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Front%20Oncol&amp;title=Could%20the%20eIF2alpha-independent%20translation%20be%20the%20achilles%20heel%20of%20cancer?&amp;volume=5&amp;publication_year=2015&amp;pages=264&amp;pmid=26636041&amp;doi=10.3389/fonc.2015.00264&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib26\"> <span class=\"label\"> 26. </span> <cite> Rajesh K, Krishnamoorthy J, Kazimierczak U, Tenkerian C, Papadakis AI, Wang S, et al. Phosphorylation of the translation initiation factor eIF2\u03b1 at serine 51 determines the cell fate decisions of Akt in response to oxidative stress. Cell Death Dis 2015;6:e1591. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/cddis.2014.554\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4669752/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/25590801/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cell%20Death%20Dis&amp;title=Phosphorylation%20of%20the%20translation%20initiation%20factor%20eIF2%CE%B1%20at%20serine%2051%20determines%20the%20cell%20fate%20decisions%20of%20Akt%20in%20response%20to%20oxidative%20stress&amp;volume=6&amp;publication_year=2015&amp;pages=e1591&amp;pmid=25590801&amp;doi=10.1038/cddis.2014.554&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib27\"> <span class=\"label\"> 27. </span> <cite> Ribas R, Pancholi S, Guest SK, Marangoni E, Gao Q, Thuleau A, et al. AKT antagonist AZD5363 influences estrogen receptor function in endocrine-resistant breast cancer and synergizes with fulvestrant (ICI182780) <em> in vivo </em> . Mol Cancer Ther 2015;14:2035\u201348. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1158/1535-7163.MCT-15-0143\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26116361/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Mol%20Cancer%20Ther&amp;title=AKT%20antagonist%20AZD5363%20influences%20estrogen%20receptor%20function%20in%20endocrine-resistant%20breast%20cancer%20and%20synergizes%20with%20fulvestrant%20(ICI182780)%20in%20vivo&amp;volume=14&amp;publication_year=2015&amp;pages=2035-48&amp;pmid=26116361&amp;doi=10.1158/1535-7163.MCT-15-0143&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib28\"> <span class=\"label\"> 28. </span> <cite> Chen X, Dai X, Zou P, Chen W, Rajamanickam V, Feng C, et al. Curcuminoid EF24 enhances the anti-tumour activity of Akt inhibitor MK-2206 through ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction in gastric cancer. Br J Pharmacol 2017;174:1131\u201346. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1111/bph.13765\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5406301/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/28255993/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Br%20J%20Pharmacol&amp;title=Curcuminoid%20EF24%20enhances%20the%20anti-tumour%20activity%20of%20Akt%20inhibitor%20MK-2206%20through%20ROS-mediated%20endoplasmic%20reticulum%20stress%20and%20mitochondrial%20dysfunction%20in%20gastric%20cancer&amp;volume=174&amp;publication_year=2017&amp;pages=1131-46&amp;pmid=28255993&amp;doi=10.1111/bph.13765&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib29\"> <span class=\"label\"> 29. </span> <cite> Bavelloni A, Piazzi M, Faenza I, Raffini M, D\u2019Angelo A, Cattini L, et al. Prohibitin 2 represents a novel nuclear AKT substrate during all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. FASEB J 2014;28:2009\u201319. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1096/fj.13-244368\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/24522204/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=FASEB%20J&amp;title=Prohibitin%202%20represents%20a%20novel%20nuclear%20AKT%20substrate%20during%20all-trans%20retinoic%20acid-induced%20differentiation%20of%20acute%20promyelocytic%20leukemia%20cells&amp;volume=28&amp;publication_year=2014&amp;pages=2009-19&amp;pmid=24522204&amp;doi=10.1096/fj.13-244368&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib30\"> <span class=\"label\"> 30. </span> <cite> McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012;3:1068\u2013111. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.18632/oncotarget.659\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3717945/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/23085539/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Ras/Raf/MEK/ERK%20and%20PI3K/PTEN/Akt/mTOR%20cascade%20inhibitors:%20how%20mutations%20can%20result%20in%20therapy%20resistance%20and%20how%20to%20overcome%20resistance&amp;volume=3&amp;publication_year=2012&amp;pages=1068-111&amp;pmid=23085539&amp;doi=10.18632/oncotarget.659&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib31\"> <span class=\"label\"> 31. </span> <cite> Bao F, Hao P, An S, Yang Y, Liu Y, Hao Q, et al. Akt scaffold proteins: the key to controlling specificity of Akt signaling. Am J Physiol Cell Physiol 2021;321:C429\u20132. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1152/ajpcell.00146.2020\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/34161152/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Am%20J%20Physiol%20Cell%20Physiol&amp;title=Akt%20scaffold%20proteins:%20the%20key%20to%20controlling%20specificity%20of%20Akt%20signaling&amp;volume=321&amp;publication_year=2021&amp;pages=C429-2&amp;pmid=34161152&amp;doi=10.1152/ajpcell.00146.2020&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib32\"> <span class=\"label\"> 32. </span> <cite> Zhou Z, Ai H, Li K, Yao X, Zhu W, Liu L, et al. Prohibitin 2 localizes in nucleolus to regulate ribosomal RNA transcription and facilitate cell proliferation in RD cells. Sci Rep 2018;8:1479. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/s41598-018-19917-7\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5784149/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/29367618/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Sci%20Rep&amp;title=Prohibitin%202%20localizes%20in%20nucleolus%20to%20regulate%20ribosomal%20RNA%20transcription%20and%20facilitate%20cell%20proliferation%20in%20RD%20cells&amp;volume=8&amp;publication_year=2018&amp;pages=1479&amp;pmid=29367618&amp;doi=10.1038/s41598-018-19917-7&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib33\"> <span class=\"label\"> 33. </span> <cite> Cizkova M, Vacher S, Meseure D, Trassard M, Susini A, Mlcuchova D, et al. PIK3R1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer 2013;13:545. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1186/1471-2407-13-545\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4225603/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/24229379/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=PIK3R1%20underexpression%20is%20an%20independent%20prognostic%20marker%20in%20breast%20cancer&amp;volume=13&amp;publication_year=2013&amp;pages=545&amp;pmid=24229379&amp;doi=10.1186/1471-2407-13-545&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib34\"> <span class=\"label\"> 34. </span> <cite> Kim SH, Seung BJ, Cho SH, Lim HY, Bae MK, Sur JH. Dysregulation of PI3K/Akt/PTEN pathway in canine mammary tumor. Animals (Basel) 2021;11:2079. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.3390/ani11072079\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC8300234/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/34359206/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Animals%20(Basel)&amp;title=Dysregulation%20of%20PI3K/Akt/PTEN%20pathway%20in%20canine%20mammary%20tumor&amp;volume=11&amp;publication_year=2021&amp;pages=2079&amp;pmid=34359206&amp;doi=10.3390/ani11072079&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib35\"> <span class=\"label\"> 35. </span> <cite> Hoehn KL, Hohnen-Behrens C, Cederberg A, Wu LE, Turner N, Yuasa T, et al. IRS1-independent defects define major nodes of insulin resistance. Cell Metab 2008;7:421\u201333. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.cmet.2008.04.005\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC2443409/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/18460333/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cell%20Metab&amp;title=IRS1-independent%20defects%20define%20major%20nodes%20of%20insulin%20resistance&amp;volume=7&amp;publication_year=2008&amp;pages=421-33&amp;pmid=18460333&amp;doi=10.1016/j.cmet.2008.04.005&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib36\"> <span class=\"label\"> 36. </span> <cite> Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009;16:21\u201332. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.ccr.2009.04.012\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC2752826/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/19573809/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=AKT-independent%20signaling%20downstream%20of%20oncogenic%20PIK3CA%20mutations%20in%20human%20cancer&amp;volume=16&amp;publication_year=2009&amp;pages=21-32&amp;pmid=19573809&amp;doi=10.1016/j.ccr.2009.04.012&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib37\"> <span class=\"label\"> 37. </span> <cite> Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. Int J Mol Sci 2015;16:21138\u201352. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.3390/ijms160921138\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4613246/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26404259/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Int%20J%20Mol%20Sci&amp;title=PI3K%20and%20AKT:%20unfaithful%20partners%20in%20cancer&amp;volume=16&amp;publication_year=2015&amp;pages=21138-52&amp;pmid=26404259&amp;doi=10.3390/ijms160921138&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib38\"> <span class=\"label\"> 38. </span> <cite> Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008;68:6084\u201391. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1158/0008-5472.CAN-07-6854\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC2680495/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/18676830/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=An%20integrative%20genomic%20and%20proteomic%20analysis%20of%20PIK3CA,%20PTEN,%20and%20AKT%20mutations%20in%20breast%20cancer&amp;volume=68&amp;publication_year=2008&amp;pages=6084-91&amp;pmid=18676830&amp;doi=10.1158/0008-5472.CAN-07-6854&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib39\"> <span class=\"label\"> 39. </span> <cite> Cancer Genome Atlas Network . Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61\u201370. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nature11412\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3465532/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/23000897/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Comprehensive%20molecular%20portraits%20of%20human%20breast%20tumours&amp;volume=490&amp;publication_year=2012&amp;pages=61-70&amp;pmid=23000897&amp;doi=10.1038/nature11412&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib40\"> <span class=\"label\"> 40. </span> <cite> O\u2019Hurley G, Daly E, O\u2019Grady A, Cummins R, Quinn C, Flanagan L, et al. Investigation of molecular alterations of AKT-3 in triple-negative breast cancer. Histopathology 2014;64:660\u201370. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1111/his.12313\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/24138071/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Histopathology&amp;title=Investigation%20of%20molecular%20alterations%20of%20AKT-3%20in%20triple-negative%20breast%20cancer&amp;volume=64&amp;publication_year=2014&amp;pages=660-70&amp;pmid=24138071&amp;doi=10.1111/his.12313&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib41\"> <span class=\"label\"> 41. </span> <cite> Lin Z, Peng R, Sun Y, Zhang L, Zhang Z. Identification of ribosomal protein family in triple-negative breast cancer by bioinformatics analysis. Biosci Rep 2021;41:BSR20200869. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1042/BSR20200869\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7789804/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/33305312/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Biosci%20Rep&amp;title=Identification%20of%20ribosomal%20protein%20family%20in%20triple-negative%20breast%20cancer%20by%20bioinformatics%20analysis&amp;volume=41&amp;publication_year=2021&amp;pages=BSR20200869&amp;pmid=33305312&amp;doi=10.1042/BSR20200869&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib42\"> <span class=\"label\"> 42. </span> <cite> Fang E, Zhang X. Identification of breast cancer hub genes and analysis of prognostic values using integrated bioinformatics analysis. Cancer Biomark 2017;21:373\u201381. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.3233/CBM-170550\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/29081411/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Biomark&amp;title=Identification%20of%20breast%20cancer%20hub%20genes%20and%20analysis%20of%20prognostic%20values%20using%20integrated%20bioinformatics%20analysis&amp;volume=21&amp;publication_year=2017&amp;pages=373-81&amp;pmid=29081411&amp;doi=10.3233/CBM-170550&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib43\"> <span class=\"label\"> 43. </span> <cite> Andrikopoulou A, Chatzinikolaou S, Panourgias E, Kaparelou M, Liontos M, Dimopoulos MA, et al. The emerging role of capivasertib in breast cancer. Breast 2022;63:157\u201367. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.breast.2022.03.018\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC9011110/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/35398754/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Breast&amp;title=The%20emerging%20role%20of%20capivasertib%20in%20breast%20cancer&amp;volume=63&amp;publication_year=2022&amp;pages=157-67&amp;pmid=35398754&amp;doi=10.1016/j.breast.2022.03.018&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib44\"> <span class=\"label\"> 44. </span> <cite> Dunn S, Eberlein C, Yu J, Gris-Oliver A, Ong SH, Yelland U, et al. AKT-mTORC1 reactivation is the dominant resistance driver for PI3K\u03b2/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors. Oncogene 2022;41:5046\u201360. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/s41388-022-02482-9\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC9652152/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/36241868/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=AKT-mTORC1%20reactivation%20is%20the%20dominant%20resistance%20driver%20for%20PI3K%CE%B2/AKT%20inhibitors%20in%20PTEN-null%20breast%20cancer%20and%20can%20be%20overcome%20by%20combining%20with%20Mcl-1%20inhibitors&amp;volume=41&amp;publication_year=2022&amp;pages=5046-60&amp;pmid=36241868&amp;doi=10.1038/s41388-022-02482-9&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib45\"> <span class=\"label\"> 45. </span> <cite> Coleman N, Subbiah V, Pant S, Patel K, Roy-Chowdhuri S, Yedururi S, et al. Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. NPJ Precis Oncol 2021;5:99. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/s41698-021-00240-w\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC8636467/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/34853384/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=NPJ%20Precis%20Oncol&amp;title=Emergence%20of%20mTOR%20mutation%20as%20an%20acquired%20resistance%20mechanism%20to%20AKT%20inhibition,%20and%20subsequent%20response%20to%20mTORC1/2%20inhibition&amp;volume=5&amp;publication_year=2021&amp;pages=99&amp;pmid=34853384&amp;doi=10.1038/s41698-021-00240-w&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib46\"> <span class=\"label\"> 46. </span> <cite> Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med 2019;25:751\u20138. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/s41591-019-0424-4\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC6599610/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/31011205/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Med&amp;title=Genomic%20and%20transcriptomic%20profiling%20expands%20precision%20cancer%20medicine:%20the%20WINTHER%20trial&amp;volume=25&amp;publication_year=2019&amp;pages=751-8&amp;pmid=31011205&amp;doi=10.1038/s41591-019-0424-4&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib47\"> <span class=\"label\"> 47. </span> <cite> Davies BR, Greenwood H, Dudley P, Crafter C, Yu D-H, Zhang J, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 2012;11:873\u201387. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1158/1535-7163.MCT-11-0824-T\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/22294718/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Mol%20Cancer%20Ther&amp;title=Preclinical%20pharmacology%20of%20AZD5363,%20an%20inhibitor%20of%20AKT:%20pharmacodynamics,%20antitumor%20activity,%20and%20correlation%20of%20monotherapy%20activity%20with%20genetic%20background&amp;volume=11&amp;publication_year=2012&amp;pages=873-87&amp;pmid=22294718&amp;doi=10.1158/1535-7163.MCT-11-0824-T&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib48\"> <span class=\"label\"> 48. </span> <cite> Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial. J Clin Oncol 2020;38:423\u201333. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1200/JCO.19.00368\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/31841354/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Capivasertib%20plus%20paclitaxel%20versus%20placebo%20plus%20paclitaxel%20as%20first-line%20therapy%20for%20metastatic%20triple-negative%20breast%20cancer:%20the%20PAKT%20trial&amp;volume=38&amp;publication_year=2020&amp;pages=423-33&amp;pmid=31841354&amp;doi=10.1200/JCO.19.00368&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib49\"> <span class=\"label\"> 49. </span> <cite> Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, et al. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. NPJ Breast Cancer 2021;7:44. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/s41523-021-00251-7\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC8052445/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/33863913/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=NPJ%20Breast%20Cancer&amp;title=Selective%20AKT%20kinase%20inhibitor%20capivasertib%20in%20combination%20with%20fulvestrant%20in%20PTEN-mutant%20ER-positive%20metastatic%20breast%20cancer&amp;volume=7&amp;publication_year=2021&amp;pages=44&amp;pmid=33863913&amp;doi=10.1038/s41523-021-00251-7&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib50\"> <span class=\"label\"> 50. </span> <cite> Turner N, Oliveira M, Howell SJ, Dalenc F, Cort\u00e9s J, Gomez H, et al. Abstract GS3-04: GS3-04 capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III CAPItello-291 trial. Cancer Res 2023;83(5_Suppl):GS3\u201304. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Abstract%20GS3-04:%20GS3-04%20capivasertib%20and%20fulvestrant%20for%20patients%20with%20aromatase%20inhibitor-resistant%20hormone%20receptor-positive/human%20epidermal%20growth%20factor%20receptor%202-negative%20advanced%20breast%20cancer:%20results%20from%20the%20phase%20III%20CAPItello-291%20trial&amp;volume=83&amp;issue=5_Suppl&amp;publication_year=2023&amp;pages=GS3-04&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"bib51\"> <span class=\"label\"> 51. </span> <cite> Gambaro K, Marques M, McNamara S, Couetoux du Tertre M, Diaz Z, Hoffert C, et al. Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer. Clin Transl Med 2021;11:e401. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1002/ctm2.401\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC8087915/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/33931971/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Clin%20Transl%20Med&amp;title=Copy%20number%20and%20transcriptome%20alterations%20associated%20with%20metastatic%20lesion%20response%20to%20treatment%20in%20colorectal%20cancer&amp;volume=11&amp;publication_year=2021&amp;pages=e401&amp;pmid=33931971&amp;doi=10.1002/ctm2.401&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> </ul> </section> </section> <section class=\"associated-data\" id=\"_ad93_\" lang=\"en\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"_ad93_-anchor\"> </a> Associated Data </h2> <p class=\"font-secondary\"> <em> This section collects any data citations, data availability statements, or supplementary materials included in this article. </em> </p> <section class=\"supplementary-materials\" id=\"_adsm93_\" lang=\"en\"> <h3 class=\"pmc_sec_title\"> Supplementary Materials </h3> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material1_reqid_\"> <div class=\"caption p\"> <span> Supplementary Methods S1 </span> <p> Supplemental Materials and Methods concerning patient samples, cell lines, tissue culture, iMALDI-MS, Nano-LC-Orbitrap-MS, LC-MRM-MS </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_methods_s1_suppsm1.pdf\"> crc-24-0113_supplementary_methods_s1_suppsm1.pdf </a> <sup> (780.8KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material2_reqid_\"> <div class=\"caption p\"> <span> Supplementary Validation Data S1 </span> <p> Supplementary Validation Data demonstrating the performance of the iMALDI-MS assay </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_validation_data_s1_suppsd1.pdf\"> crc-24-0113_supplementary_validation_data_s1_suppsd1.pdf </a> <sup> (365.6KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material3_reqid_\"> <div class=\"caption p\"> <span> Supplementary Validation Data S2 </span> <p> Quality Assessment of the Global Proteomics Data </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_validation_data_s2_suppsd2.pdf\"> crc-24-0113_supplementary_validation_data_s2_suppsd2.pdf </a> <sup> (121.9KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material4_reqid_\"> <div class=\"caption p\"> <span> Supplementary Figure S1 </span> <p> Individual protein concentrations measured by iMALDI-MS for each sample, comparison of measured PTEN concentration to IHC H-score </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_figure_s1_suppsf1.pdf\"> crc-24-0113_supplementary_figure_s1_suppsf1.pdf </a> <sup> (387.1KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material5_reqid_\"> <div class=\"caption p\"> <span> Supplementary Figure S2 </span> <p> Individual protein concentrations measured by iMALDI-MS for PTEN vs. IHC H-score </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_figure_s2_suppsf2.pdf\"> crc-24-0113_supplementary_figure_s2_suppsf2.pdf </a> <sup> (372KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material6_reqid_\"> <div class=\"caption p\"> <span> Supplementary Figure S3 </span> <p> Comparison of iMALDI and Global Proteomics results for primary vs metastatic samples </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_figure_s3_suppsf3.pdf\"> crc-24-0113_supplementary_figure_s3_suppsf3.pdf </a> <sup> (492.6KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material7_reqid_\"> <div class=\"caption p\"> <span> Supplementary Figure S4 </span> <p> Combination treatment of cell lines with capivasertib and an eIF2\u03b1 inhibitor </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_figure_s4_suppsf4.pdf\"> crc-24-0113_supplementary_figure_s4_suppsf4.pdf </a> <sup> (1.2MB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material8_reqid_\"> <div class=\"caption p\"> <span> Supplementary Table S1 </span> <p> Detailed results of the label-free quantitation </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_table_s1_suppst1.pdf\"> crc-24-0113_supplementary_table_s1_suppst1.pdf </a> <sup> (110.9KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material9_reqid_\"> <div class=\"caption p\"> <span> Supplementary Table S2 </span> <p> Proteins expression differences between capivasertib-resistant vs. capivasertib-sensitive cells quantified by validated MRM-MS assays as compared to the profile observed in patient samples </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_table_s2_suppst2.pdf\"> crc-24-0113_supplementary_table_s2_suppst2.pdf </a> <sup> (122.2KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material10_reqid_\"> <div class=\"caption p\"> <span> Supplementary Table S3 </span> <p> Detailed results of pathway mapping by Qiagen IPA </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11320025/bin/crc-24-0113_supplementary_table_s3_suppst3.pdf\"> crc-24-0113_supplementary_table_s3_suppst3.pdf </a> <sup> (109.5KB, pdf) </sup> </div> </div> </section> </section> <section class=\"data-availability-statement\" id=\"_adda93_\" lang=\"en\"> <h3 class=\"pmc_sec_title\"> Data Availability Statement </h3> <p> Individual participant data associated with the clinical trials sponsored by AstraZeneca can be requested by qualified researchers via the request portal, with request evaluated according to the AstraZeneca disclosure commitment ( <a class=\"usa-link usa-link--external\" href=\"https://astrazenecagroup-dt.pharmacm.com/DT/Home\" rel=\"noopener noreferrer\" target=\"_blank\"> https://astrazenecagroup-dt.pharmacm.com/DT/Home </a> ) and Responsible Data Sharing Principles. Global proteomics spectra and associated were deposited to the ProteomeXchange Consortium ( <a class=\"usa-link usa-link--external\" href=\"https://www.proteomexchange.org/\" rel=\"noopener noreferrer\" target=\"_blank\"> https://www.proteomexchange.org/ </a> ) via the PRIDE partner repository with the dataset identifier PXD052949. Samples of the polyclonal antibodies for AKT1 and AKT2 can be requested through the Segal Cancer Proteomics Centre (Montreal, QC, Canada). LC-MRM-MS assay information and validation data are publicly available in the CPTAC Assay Portal ( <a class=\"usa-link usa-link--external\" href=\"https://assays.cancer.gov/available_assays\" rel=\"noopener noreferrer\" target=\"_blank\"> https://assays.cancer.gov/available_assays </a> , IDs: 6077-6129; see Supplementary Methods S1 for links to each assay). MRM-MS assay kits including the required peptide standards and instrument files are now commercially available from MRM Proteomics Inc. (Montreal, QC, Canada). </p> </section> </section> </section> <footer class=\"p courtesy-note font-secondary font-sm text-center\"> <hr class=\"headless\"/> <p> Articles from Cancer Research Communications are provided here courtesy of <strong> American Association for Cancer Research </strong> </p> </footer> </section> </article> </main> </div> </div> </div> <div class=\"pmc-sidenav desktop:grid-col-4 display-flex\"> <section aria-label=\"Article resources and navigation\" class=\"pmc-sidenav__container\"> <button class=\"usa-button pmc-sidenav__container__close usa-button--unstyled\" type=\"button\"> <img alt=\"Close\" role=\"img\" src=\"/static/img/usa-icons/close.svg\"/> </button> <div class=\"display-none desktop:display-block\"> <section class=\"margin-top-4 desktop:margin-top-0\"> <h2 class=\"margin-top-0\"> ACTIONS </h2> <ul class=\"usa-list usa-list--unstyled usa-list--actions\"> <li> <a class=\"usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1\" href=\"https://doi.org/10.1158/2767-9764.CRC-24-0113\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#launch\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1 padding-right-2\"> View on publisher site </span> </a> </li> <li> <a class=\"usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1\" href=\"pdf/crc-24-0113.pdf\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#file_download\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1\"> PDF (25.1 MB) </span> </a> </li> <li> <button aria-label=\"Open dialog with citation text in different styles\" class=\"usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1\" role=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#format_quote\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1 button-label\"> Cite </span> </button> </li> <li> <button aria-label=\"Save article in MyNCBI collections.\" class=\"usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3 usa-icon--bookmark-full\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-full.svg#icon\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3 usa-icon--bookmark-empty\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-empty.svg#icon\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1\"> Collections </span> </button> </li> <li class=\"pmc-permalink\"> <button aria-expanded=\"false\" aria-haspopup=\"true\" aria-label=\"Show article permalink\" class=\"usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#share\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1 button-label\"> Permalink </span> </button> <div class=\"pmc-permalink__dropdown\" hidden=\"\"> <div class=\"pmc-permalink__dropdown__container\"> <h2 class=\"usa-modal__heading margin-top-0 margin-bottom-2\"> PERMALINK </h2> <div class=\"pmc-permalink__dropdown__content\"> <input aria-label=\"Article permalink\" class=\"usa-input\" type=\"text\" value=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11320025/\"/> <button aria-expanded=\"false\" class=\"usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0\" title=\"Copy article permalink\"> <svg aria-hidden=\"true\" class=\"usa-icon\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#content_copy\"> </use> </svg> <span class=\"margin-left-1\"> Copy </span> </button> </div> </div> </div> </li> </ul> </section> </div> <section class=\"pmc-resources margin-top-6 desktop:margin-top-4\"> <h2 class=\"margin-top-0\"> RESOURCES </h2> <div class=\"usa-accordion usa-accordion--multiselectable\"> <h3 class=\"usa-accordion__heading\"> <button aria-controls=\"resources-similar-articles\" aria-expanded=\"false\" class=\"usa-accordion__button\" type=\"button\"> Similar articles </button> </h3> <div class=\"usa-accordion__content usa-prose\" hidden=\"\" id=\"resources-similar-articles\"> </div> <h3 class=\"usa-accordion__heading\"> <button aria-controls=\"resources-cited-by-other-articles\" aria-expanded=\"false\" class=\"usa-accordion__button\" type=\"button\"> Cited by other articles </button> </h3> <div class=\"usa-accordion__content usa-prose\" hidden=\"\" id=\"resources-cited-by-other-articles\"> </div> <h3 class=\"usa-accordion__heading\"> <button aria-controls=\"resources-links-to-ncbi-databases\" aria-expanded=\"false\" class=\"usa-accordion__button\" type=\"button\"> Links to NCBI Databases </button> </h3> <div class=\"usa-accordion__content usa-prose\" hidden=\"\" id=\"resources-links-to-ncbi-databases\"> </div> </div> </section> <section class=\"usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4\"> <nav aria-label=\"On this page\" class=\"usa-in-page-nav__nav\"> <h2 class=\"usa-in-page-nav__heading\" tabindex=\"0\"> On this page </h2> <ul class=\"usa-in-page-nav__list\"> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#abstract1\"> Abstract </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#s1\"> Introduction </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#s2\"> Materials and Methods </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#s3\"> Results </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#s4\"> Discussion </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#s5\"> Conclusion </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec18\"> Supplementary Material </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#ack1\"> Acknowledgments </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#app1\"> Appendix Gene and protein names. </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#fn-group1\"> Footnotes </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#s6\"> Authors\u2019 Disclosures </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#s7\"> Authors\u2019 Contributions </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#ref-list1\"> References </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#_ad93_\"> Associated Data </a> </li> </ul> </nav> </section> </section> </div> <div aria-label=\"Citation Dialog\" class=\"overlay citation-dialog-overlay\" role=\"dialog\"> <div aria-hidden=\"true\" class=\"dialog citation-dialog\" role=\"document\"> <div class=\"display-inline-flex flex-align-center flex-justify width-full margin-bottom-2\"> <h2 class=\"usa-modal__heading margin-0\"> Cite </h2> <button class=\"usa-button usa-button--unstyled close-overlay text-black width-auto\" tabindex=\"1\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#close\"> </use> </svg> </button> </div> <div class=\"citation-text-block\"> <div class=\"citation-text margin-bottom-2\"> </div> <ul class=\"usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center\"> <li> <button class=\"usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus\" tabindex=\"2\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#content_copy\"> </use> </svg> <span> Copy </span> </button> </li> <li> <a class=\"usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button\" href=\"#\" role=\"button\" tabindex=\"3\" title=\"Download a file for external citation management software\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#file_download\"> </use> </svg> <span class=\"display-none mobile-lg:display-inline\"> Download .nbib </span> <span class=\"display-inline mobile-lg:display-none\"> .nbib </span> </a> </li> <li> <div class=\"display-inline-flex flex-align-center\"> <label class=\"usa-label margin-top-0\"> Format: </label> <select aria-label=\"Format\" class=\"usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4\" tabindex=\"4\"> <option value=\"AMA\"> AMA </option> <option value=\"APA\"> APA </option> <option value=\"MLA\"> MLA </option> <option selected=\"selected\" value=\"NLM\"> NLM </option> </select> </div> </li> </ul> <div class=\"dots-loading-indicator citation-loading-indicator\"> <div class=\"dot dot-1\"> </div> <div class=\"dot dot-2\"> </div> <div class=\"dot dot-3\"> </div> </div> </div> </div> </div> <div class=\"overlay collections-dialog-overlay\" role=\"dialog\"> <div aria-hidden=\"true\" class=\"dialog collections-dialog\" id=\"collections-action-dialog\" role=\"document\"> <div class=\"display-inline-flex flex-align-center flex-justify width-full margin-bottom-2\"> <h2 class=\"usa-modal__heading margin-0\"> Add to Collections </h2> </div> <div class=\"collections-action-panel action-panel\"> <form class=\"usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors\" id=\"collections-action-dialog-form\"> <fieldset class=\"usa-fieldset margin-bottom-2\"> <div class=\"usa-radio\"> <input class=\"usa-radio__input usa-radio__input--tile collections-new margin-top-0\" id=\"collections-action-dialog-new\" name=\"collections\" type=\"radio\" value=\"new\"/> <label class=\"usa-radio__label\" for=\"collections-action-dialog-new\"> Create a new collection </label> </div> <div class=\"usa-radio\"> <input checked=\"true\" class=\"usa-radio__input usa-radio__input--tile collections-existing\" id=\"collections-action-dialog-existing\" name=\"collections\" type=\"radio\" value=\"existing\"/> <label class=\"usa-radio__label\" for=\"collections-action-dialog-existing\"> Add to an existing collection </label> </div> </fieldset> <fieldset class=\"usa-fieldset margin-bottom-2\"> <div class=\"action-panel-control-wrap new-collections-controls\"> <label class=\"usa-label margin-top-0\" for=\"collections-action-dialog-add-to-new\"> Name your collection <abbr class=\"usa-hint usa-hint--required text-no-underline\" title=\"required\"> * </abbr> </label> <input class=\"usa-input collections-action-add-to-new\" id=\"collections-action-dialog-add-to-new\" maxlength=\"\" name=\"add-to-new-collection\" pattern='[^\"&amp;=&lt;&gt;/]*' required=\"\" title='The following characters are not allowed in the Name field: \"&amp;=&lt;&gt;/' type=\"text\"/> </div> <div class=\"action-panel-control-wrap existing-collections-controls\"> <label class=\"usa-label margin-top-0\" for=\"collections-action-dialog-add-to-existing\"> Choose a collection </label> <select class=\"usa-select collections-action-add-to-existing\" id=\"collections-action-dialog-add-to-existing\"> </select> <div class=\"collections-retry-load-on-error usa-input-error-message selection-validation-message\"> Unable to load your collection due to an error <br/> <a href=\"#\"> Please try again </a> </div> </div> </fieldset> <div class=\"display-inline-flex\"> <button class=\"usa-button margin-top-0 action-panel-submit\" type=\"submit\"> Add </button> <button aria-label=\"Close 'Add to Collections' panel\" class=\"usa-button usa-button--outline margin-top-0 action-panel-cancel\" ref=\"linksrc=close_collections_panel\"> Cancel </button> </div> </form> </div> </div> </div> </div> </div> </div> <footer class=\"ncbi-footer ncbi-dark-background\"> <div class=\"ncbi-footer__icon-section\"> <div class=\"ncbi-footer__social-header\"> Follow NCBI </div> <div class=\"grid-container ncbi-footer__ncbi-social-icons-container\"> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://twitter.com/ncbi\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"40\" viewbox=\"0 0 40 40\" width=\"40\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on X (formerly known as Twitter) </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://www.facebook.com/ncbi.nlm\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"29\" viewbox=\"0 0 16 29\" width=\"16\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on Facebook </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://www.linkedin.com/company/ncbinlm\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"23\" viewbox=\"0 0 26 24\" width=\"25\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z\"> </path> <path d=\"M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z\"> </path> <path d=\"M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on LinkedIn </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://github.com/ncbi\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"27\" viewbox=\"0 0 28 28\" width=\"28\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on GitHub </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://ncbiinsights.ncbi.nlm.nih.gov/\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"26\" viewbox=\"0 0 27 27\" width=\"26\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z\"> </path> <path d=\"M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z\"> </path> <path d=\"M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI RSS feed </span> </a> </div> </div> <div class=\"grid-container ncbi-footer__container\"> <div class=\"grid-row ncbi-footer__main-content-container\"> <div class=\"ncbi-footer__column\"> <p class=\"ncbi-footer__circled-icons-heading\"> Connect with NLM </p> <div class=\"ncbi-footer__circled-icons-list\"> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--circled\" href=\"https://twitter.com/nlm_nih\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"32\" viewbox=\"0 0 40 40\" width=\"32\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z\"> </path> </svg> <span class=\"usa-sr-only\"> NLM on X (formerly known as Twitter) </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--circled\" href=\"https://www.facebook.com/nationallibraryofmedicine\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"24\" viewbox=\"0 0 13 24\" width=\"13\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z\"> </path> </svg> <span class=\"usa-sr-only\"> NLM on Facebook </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--circled\" href=\"https://www.youtube.com/user/NLMNIH\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"15\" viewbox=\"0 0 21 15\" width=\"21\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z\" fill=\"white\"> </path> </svg> <span class=\"usa-sr-only\"> NLM on YouTube </span> </a> </div> </div> <address class=\"ncbi-footer__address ncbi-footer__column\"> <p> <a class=\"usa-link usa-link--external\" href=\"https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508, -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508! 4d-77.0988323\" rel=\"noopener noreferrer\" target=\"_blank\"> National Library of Medicine <br/> 8600 Rockville Pike <br/> Bethesda, MD 20894 </a> </p> </address> <ul class=\"usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column\"> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/web_policies.html\"> Web Policies </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office\"> FOIA </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--external usa-link--alt ncbi-footer__link\" href=\"https://www.hhs.gov/vulnerability-disclosure-policy/index.html\" rel=\"noreferrer noopener\" target=\"_blank\"> HHS Vulnerability Disclosure </a> </li> </ul> <ul class=\"usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column\"> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://support.nlm.nih.gov/?pagename=cloudpmc-viewer%3Apmc%3Aarticle%3Ajournal\"> Help </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/accessibility.html\"> Accessibility </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/careers/careers.html\"> Careers </a> </li> </ul> </div> <div class=\"grid-row grid-col-12\"> <ul class=\"ncbi-footer__bottom-links-list\"> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/\"> NLM </a> </li> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nih.gov/\"> NIH </a> </li> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--external usa-link--alt ncbi-footer__link\" href=\"https://www.hhs.gov/\" rel=\"noreferrer noopener\" target=\"_blank\"> HHS </a> </li> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--external usa-link--alt ncbi-footer__link\" href=\"https://www.usa.gov/\" rel=\"noreferrer noopener\" target=\"_blank\"> USA.gov </a> </li> </ul> </div> </div> </footer> <div id=\"ZN_dikYWqsjiUWN0Q5\"> </div> <button class=\"back-to-top\"> <label> Back to Top </label> <svg aria-hidden=\"true\" class=\"usa-icon order-0\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#arrow_upward\"> </use> </svg> </button> <div class=\"fake-body-scroll\"> </div> <div class=\"fake-body-scroll\"> </div> <div class=\"QSIFeedbackButton\"> <button aria-label=\"Tell us what you think!\" id=\"QSIFeedbackButton-btn\" role=\"button\"> <img alt=\"Tell us what you think!\" src=\"https://iad1.qualtrics.com/WRQualtricsSiteIntercept/Graphic.php?IM=IM_3xWqwNkIHc7cA0S\"/> </button> </div> </body> </html>) and a list of known data repositories (bigd.big.ac.cn, massive.ucsd.edu, www.ebi.ac.uk, www.iprox.cn, proteomecentral.proteomexchange.org, www.proteomexchange.org, pdc.cancer.gov, doi.org, www.ncbi.nlm.nih.gov). Given this information, please return a JSON array of objects where each object has the following structure:\n- `dataset_identifier`: The dataset identifier (a code). If not found, set it to \"n/a\".\n- `repository_reference`: The URL or reference to the data repository. If not found, set it to \"n/a\".\n\nPlease follow these strict instructions:\n- The output must be a valid JSON array of objects.\n- Each object must contain the keys `dataset_identifier` and `repository_reference`.\n- Any other output format will be considered invalid."}]}]